Amarenco P, Duyckaerts C, Tzourio C, H nin D, Bousser MG, Hauw JJ. The prevalence of ulcerated plaques in the aortic arch in patients with stroke. N 387. Amarenco P, Cohen A, Tzourio C, Bertrand B, Hommel M, Besson G, Chauvel C, Touboul PJ, Bousser MG. Atherosclerotic disease of the aortic arch and the risk of ischemic stroke. N Engl J Med. 1994;331:1474 1479. 388. Di Tullio MR, Russo C, Jin Z, Sacco RL, Mohr JP, Homma S; Patent Foramen Ovale in Cryptogenic Stroke Study Investigators. Aortic arch plaques and risk of recurrent stroke and death. Circulation. 2009;119:2376 2382. doi: 389. Cohen A, Tzourio C, Bertrand B, Chauvel C, Bousser MG, Amarenco P. Aortic plaque morphology and vascular events: a follow-up study in patients with ischemic stroke: FAPS Investigators: French Study of Aortic Plaques in Stroke. Circulation. 1997;96:3838 3841. doi: 10.1161/01.cir.96.11.3838 390. Amarenco P, Cohen A, Hommel M, Moulin T, Leys D, Bousser MG. Atherosclerotic disease of the aortic arch as a risk factor for recurrent ischemic stroke. N Engl J Med. 1996;334:1216 1221. 391. Deng X, Gao F, Zhang D, Zhang Y, Wang R, Wang S, Cao Y, Zhao Y, Pan Y, Liu X, et al. Direct versus indirect bypasses for adult ischemic-type moyamoya disease: a propensity score-matched analysis. J Neurosurg. 392. Deng X, Gao F, Zhang D, Zhang Y, Wang R, Wang S, Cao Y, Zhao Y, Pan Y, Ye X, et al. Effects of different surgical modalities on the clinical out- come of patients with moyamoya disease: a prospective cohort study. J 393. Jeon JP, Kim JE, Cho WS, Bang JS, Son YJ, Oh CW. Meta-analysis of the surgical outcomes of symptomatic moyamoya disease in adults. J 394.


Meta-analysis of the surgical outcomes of symptomatic moyamoya disease in adults. J 394. Li Q, Gao Y, Xin W, Zhou Z, Rong H, Qin Y, Li K, Zhou Y, Wang J, Xiong J, et al. Meta-analysis of prognosis of different treatments for symptom- atic moyamoya disease. World Neurosurg. 2019;127:354 361. doi: 395. Sun H, Wilson C, Ozpinar A, Safavi-Abbasi S, Zhao Y, Nakaji P, Wanebo JE, Spetzler RF. Perioperative complications and long-term outcomes after bypasses in adults with moyamoya disease: a systematic re- view and meta-analysis. World Neurosurg. 2016;92:179 188. doi: 396. Kim H, Jang DK, Han YM, Sung JH, Park IS, Lee KS, Yang JH, Huh PW, Park YS, Kim DS, et al. Direct bypass versus indirect bypass in adult moy- amoya angiopathy with symptoms or hemodynamic instability: a meta- analysis of comparative studies. World Neurosurg. 2016;94:273 284. doi: 397. Jang DK, Lee KS, Rha HK, Huh PW, Yang JH, Park IS, Ahn JG, Sung JH, Han YM. Bypass surgery versus medical treatment for symptom- atic moyamoya disease in adults. J Neurosurg. 2017;127:492 502. doi: 398. Yamada S, Oki K, Itoh Y, Kuroda S, Houkin K, Tominaga T, Miyamoto S, Hashimoto N, Suzuki N; Research Committee on Spontaneous Occlusion of Circle of Willis (Moyamoya Disease). Effects of surgery and antiplate- let therapy in ten-year follow-up from the registry study of Research Committee on Moyamoya Disease in Japan. J Stroke Cerebrovasc Dis. CLINICAL STATEMENTS AND GUIDELINES Kleindorfer 399. Qian C, Yu X, Li J, Chen J, Wang L, Chen G. The efficacy of surgical treat- ment for the secondary prevention of stroke in symptomatic moyamoya disease: a meta-analysis. Medicine (Baltimore). 2015;94:e2218. doi: 400. Onozuka D, Hagihara A, Nishimura K, Kada A, Nakagawara J, Ogasawara K, Ono J, Shiokawa Y, Aruga T, Miyachi S, et al; J-ASPECT Study Collaborators.


Onozuka D, Hagihara A, Nishimura K, Kada A, Nakagawara J, Ogasawara K, Ono J, Shiokawa Y, Aruga T, Miyachi S, et al; J-ASPECT Study Collaborators. Prehospital antiplatelet use and functional status on ad- mission of patients with non-haemorrhagic moyamoya disease: a na- tionwide retrospective cohort study (J-ASPECT study). BMJ Open. 401. Zhao Y, Zhang Q, Zhang D, Zhao Y. Effect of aspirin in postoperative management of adult ischemic moyamoya disease. World Neurosurg. 402. Acker G, Goerdes S, Schneider UC, Schmiedek P, Czabanka M, Vajkoczy P. Distinct clinical and radiographic characteristics of moyamoya disease amongst European Caucasians. Eur J Neurol. 2015;22:1012 1017. doi: 403. Baba T, Houkin K, Kuroda S. Novel epidemiological features of moy- amoya disease. J Neurol Neurosurg Psychiatry. 2008;79:900 904. doi: 404. Research Committee on the Pathology and Treatment of Spontaneous Occlusion of the Circle of Willis. Guidelines for diagnosis and treatment of moyamoya disease (spontaneous occlusion of the circle of Willis). Neurol Med Chir (Tokyo). 2012;52:245 266. doi: 10.2176/nmc.52.245 405. Miyamoto S, Yoshimoto T, Hashimoto N, Okada Y, Tsuji I, Tominaga T, Nakagawara J, Takahashi JC; JAM Trial Investigators. Effects of extracra- nial-intracranial bypass for patients with hemorrhagic moyamoya disease: results of the Japan Adult Moyamoya Trial. Stroke. 2014;45:1415 1421. 406. Kim DY, Son JP, Yeon JY, Kim GM, Kim JS, Hong SC, Bang OY. Infarct pattern and collateral status in adult moyamoya disease: a multimodal magnetic resonance imaging study. Stroke. 2017;48:111 116. doi: 407. Kraemer M, Berlit P, Diesner F, Khan N. What is the expert s option on an- tiplatelet therapy in moyamoya disease? Results of a worldwide survey. Eur J Neurol. 2012;19:163 167. doi: 10.1111/j.1468-1331.2011.03481.x 408. Benavente OR, White CL, Pearce L, Pergola P, Roldan A, Benavente MF, Coffey C, McClure LA, Szychowski JM, Conwit R, et al; SPS3 Investigators.


Benavente OR, White CL, Pearce L, Pergola P, Roldan A, Benavente MF, Coffey C, McClure LA, Szychowski JM, Conwit R, et al; SPS3 Investigators. The Secondary Prevention of Small Subcortical Strokes (SPS3) study. Int J 409. Pan Y, Elm JJ, Li H, Easton JD, Wang Y, Farrant M, Meng X, Kim AS, Zhao X, Meurer WJ, et al. Outcomes associated with clopidogrel-aspirin use in minor stroke or transient ischemic attack: a pooled analysis of Clopidogrel in High-Risk Patients With Acute Non-Disabling Cerebrovascular Events (CHANCE) and Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trials. JAMA Neurol. 2019;76:1466 1473. doi: 410. Wang Y, Wang Y, Zhao X, Liu L, Wang D, Wang C, Wang C, Li H, Meng X, Cui L, et al; CHANCE Investigators. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med. 2013;369:11 19. doi: 411. Deleted in proofs. 412. Bamford J, Sandercock P, Jones L, Warlow C. The natural history of la- cunar infarction: the Oxfordshire Community Stroke Project. Stroke. 413. Jackson C, Sudlow C. Comparing risks of death and recurrent vascular events between lacunar and non-lacunar infarction. Brain. 2005;128(pt 414. Jacova C, Pearce LA, Costello R, McClure LA, Holliday SL, Hart RG, Benavente OR. Cognitive impairment in lacunar strokes: the SPS3 trial. Ann Neurol. 2012;72:351 362. doi: 10.1002/ana.23733 415. Makin SD, Turpin S, Dennis MS, Wardlaw JM. Cognitive impairment after lacunar stroke: systematic review and meta-analysis of incidence, prev- alence and comparison with other stroke subtypes. J Neurol Neurosurg 416. Gotoh F, Tohgi H, Hirai S, Terashi A, Fukuuchi Y, Otomo E, Shinohara Y, Itoh E, Matsuda T, Sawada T, et al. Cilostazol stroke prevention study: a placebo-controlled double-blind trial for secondary prevention of ce- rebral infarction. J Stroke Cerebrovasc Dis. 2000;9:147 157. doi: 417.


Cilostazol stroke prevention study: a placebo-controlled double-blind trial for secondary prevention of ce- rebral infarction. J Stroke Cerebrovasc Dis. 2000;9:147 157. doi: 417. Shinohara Y, Katayama Y, Uchiyama S, Yamaguchi T, Handa S, Matsuoka K, Ohashi Y, Tanahashi N, Yamamoto H, Genka C, et al; CSPS 2 Group. Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin- controlled, double-blind, randomised non-inferiority trial. Lancet Neurol. 418. Smith EE, Saposnik G, Biessels GJ, Doubal FN, Fornage M, Gorelick PB, Greenberg SM, Higashida RT, Kasner SE, Seshadri S; on be- half of the American Heart Association Stroke Council; Council on Cardiovascular Radiology and Intervention; Council on Functional Genomics and Translational Biology; and Council on Hypertension. Prevention of stroke in patients with silent cerebrovascular disease: a sci- entific statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2017;48:e44 e71. doi: 419. Stroke Prevention in Atrial Fibrillation Investigators. Stroke Prevention in Atrial Fibrillation study: final results. Circulation. 1991;84:527 39. 420. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on Atrial Fibrillation. Chest. 2010;137:263 272. doi: 10.1378/chest.09-1584 421. Mason PK, Lake DE, DiMarco JP, Ferguson JD, Mangrum JM, Bilchick K, Moorman LP, Moorman JR. Impact of the CHA2DS2-VASc score on anticoagulation recommendations for atrial fibrillation. Am J Med. 422. Olesen JB, Torp-Pedersen C, Hansen ML, Lip GY. The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0-1: a nationwide cohort study. Thromb Haemost. 2012;107:1172 1179. doi: 10.1160/TH12-03-0175 423. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, et al; RE-LY Steering Committee and Investigators.


Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, et al; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139 1151. doi: 424. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, et al; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 425. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, et al; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrilla- tion. N Engl J Med. 2011;365:981 992. doi: 10.1056/NEJMoa1107039 426. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, Waldo AL, Ezekowitz MD, Weitz JI, pinar J, et al; ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093 2104. doi: 10.1056/NEJMoa1310907 427. Healey JS, Connolly SJ, Gold MR, Israel CW, Van Gelder IC, Capucci A, Lau CP, Fain E, Yang S, Bailleul C, et al; ASSERT Investigators. Subclinical atrial fibrillation and the risk of stroke. N Engl J Med. 2012;366:120 129. doi: 428. Hart RG, Coull BM, Hart D. Early recurrent embolism associated with non- valvular atrial fibrillation: a retrospective study. Stroke. 1983;14:688 693. 429. Seiffge DJ, Werring DJ, Paciaroni M, Dawson J, Warach S, Milling TJ, Engelter ST, Fischer U, Norrving B. Timing of anticoagulation after re- cent ischaemic stroke in patients with atrial fibrillation. Lancet Neurol. 430. Paciaroni M, Agnelli G, Corea F, Ageno W, Alberti A, Lanari A, Caso V, Micheli S, Bertolani L, Venti M, et al.


Paciaroni M, Agnelli G, Corea F, Ageno W, Alberti A, Lanari A, Caso V, Micheli S, Bertolani L, Venti M, et al. Early hemorrhagic transformation of brain infarction: rate, predictive factors, and influence on clinical outcome: results of a prospective multicenter study. Stroke. 2008;39:2249 2256. 431. Ahmed N, Steiner T, Caso V, Wahlgren N; ESO-KSU Session Participants. Recommendations from the ESO-Karolinska Stroke Update Conference, Stockholm 13-15 November 2016. Eur Stroke J. 2017;2:95 102. doi: 432. Blackshear JL, Odell JA. Appendage obliteration to reduce stroke in cardi- ac surgical patients with atrial fibrillation. Ann Thorac Surg. 1996;61:755 433. Holmes DR Jr, Kar S, Price MJ, Whisenant B, Sievert H, Doshi SK, Huber K, Reddy VY. Prospective randomized evaluation of the Watchman left atrial appendage closure device in patients with atrial fibrillation versus long- term warfarin therapy: the PREVAIL trial. J Am Coll Cardiol. 2014;64:1 12. 434. Holmes DR, Reddy VY, Turi ZG, Doshi SK, Sievert H, Buchbinder M, Mullin CM, Sick P; PROTECT AF Investigators. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet. 435. Reddy VY, Doshi SK, Kar S, Gibson DN, Price MJ, Huber K, Horton RP, Buchbinder M, Neuzil P, Gordon NT, et al; PREVAIL and PROTECT AF CLINICAL STATEMENTS AND GUIDELINES Kleindorfer Investigators. 5-Year outcomes after left atrial appendage closure: from the PREVAIL and PROTECT AF trials. J Am Coll Cardiol. 2017;70:2964 436. Reddy VY, Sievert H, Halperin J, Doshi SK, Buchbinder M, Neuzil P, Huber K, Whisenant B, Kar S, Swarup V, et al; PROTECT AF Steering Committee and Investigators. Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial. JAMA. 2014;312:1988 437.


Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial. JAMA. 2014;312:1988 437. Abdul-Rahim AH, Fulton RL, Frank B, Tatlisumak T, Paciaroni M, Caso V, Diener HC, Lees KR; VISTA Collaborators. Association of improved outcome in acute ischaemic stroke patients with atrial fibrillation who receive early antithrombotic therapy: analysis from VISTA. Eur J Neurol. 438. Siontis KC, Zhang X, Eckard A, Bhave N, Schaubel DE, He K, Tilea A, Stack AG, Balkrishnan R, Yao X, et al. Outcomes associated with apix- aban use in patients with end-stage kidney disease and atrial fibril- lation in the United States. Circulation. 2018;138:1519 1529. doi: 439. Gage BF, van Walraven C, Pearce L, Hart RG, Koudstaal PJ, Boode BS, Petersen P. Selecting patients with atrial fibrillation for antico- agulation: stroke risk stratification in patients taking aspirin. Circulation. 440. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285:2864 441. G rdo an M, Ari H, Tenekecio lu E, Ari S, Bozat T, Koca V, Melek M. Predictors of atrial fibrillation recurrence in hyperthyroid and euthyroid pa- tients. Arq Bras Cardiol. 2016;106:84 91. doi: 10.5935/abc.20160013 442. Lowres N, Mulcahy G, Jin K, Gallagher R, Neubeck L, Freedman B. Incidence of postoperative atrial fibrillation recurrence in patients dis- charged in sinus rhythm after cardiac surgery: a systematic review and meta-analysis. Interact Cardiovasc Thorac Surg. 2018;26:504 511. doi: 443. Park-Hansen J, Greve AM, Clausen J, Holme SJ, Carranza CL, Irmukhamedov A, Sabah L, Lin Q, Madsen AS, Dom nguez H. New- onset of postoperative atrial fibrillation is likely to recur in the absence of other triggers. Ther Clin Risk Manag. 2018;14:1641 1647. doi: 444.


Park-Hansen J, Greve AM, Clausen J, Holme SJ, Carranza CL, Irmukhamedov A, Sabah L, Lin Q, Madsen AS, Dom nguez H. New- onset of postoperative atrial fibrillation is likely to recur in the absence of other triggers. Ther Clin Risk Manag. 2018;14:1641 1647. doi: 444. Siu CW, Jim MH, Zhang X, Chan YH, Pong V, Kwok J, Kung AW, Lau CP, Tse HF. Comparison of atrial fibrillation recurrence rates after success- ful electrical cardioversion in patients with hyperthyroidism-induced ver- sus non-hyperthyroidism-induced persistent atrial fibrillation. Am J Cardiol. 445. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, Camm AJ, Weitz JI, Lewis BS, Parkhomenko A, et al. Comparison of the efficacy and safety of new oral anticoagulants with war- farin in patients with atrial fibrillation: a meta-analysis of randomised trials. 446. Brembilla-Perrot B, Girerd N, Sellal JM, Olivier A, Manenti V, Villemin T, Beurrier D, DE Chillou C, Louis P, Selton O, et al. Risk of atrial fibrillation after atrial flutter ablation: impact of AF history, gender, and antiarrhyth- mic drug medication. J Cardiovasc Electrophysiol. 2014;25:813 820. doi: 447. Active Writing Group of the ACTIVE Investigators, Connolly S, Pogue J, Hart R, Pfeffer M, Hohnloser S, Chrolavicius S, Pfeffer M, Hohnloser S, Yusuf S. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibril- lation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for preven- tion of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet. 448. Jaillard A, Cornu C, Durieux A, Moulin T, Boutitie F, Lees KR, Hommel M. Hemorrhagic transformation in acute ischemic stroke: the MAST-E study: MAST-E group. Stroke. 1999;30:1326 1332. doi: 449. Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, Biller J, Brown M, Demaerschalk BM, et al; on behalf of the American Heart Association Stroke Council.


Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, Biller J, Brown M, Demaerschalk BM, et al; on behalf of the American Heart Association Stroke Council. 2018 Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association [published correction appears in Stroke. 2018;49:e138 and Stroke. 2018;49:e233 e234]. Stroke. 2018;49:e46 e110. doi: 450. Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L, Georg Haeusler K, Oldgren J, Reinecke H, Roldan-Schilling V, et al; ESC Scientific Document Group. The 2018 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral an- ticoagulants in patients with atrial fibrillation: executive summary. Europace. 451. Muscari A, Faccioli L, Lega MV, Lorusso A, Masetti M, Pastore Trossello M, Puddu GM, Spinardi L, Zoli M. Predicting hemorrhagic transformation and its timing from maximum cerebral lesion diameter in nonlacunar ischemic strokes. Brain Behav. 2020;10:e01497. doi: 10.1002/brb3.1497 452. Pan KL, Singer DE, Ovbiagele B, Wu YL, Ahmed MA, Lee M. Effects of non-vitamin K antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and valvular heart disease: a system- atic review and meta-analysis. J Am Heart Assoc. 2017;6:e005835. doi: 453. Avezum A, Lopes RD, Schulte PJ, Lanas F, Gersh BJ, Hanna M, Pais P, Erol C, Diaz R, Bahit MC, et al. Apixaban in comparison with warfarin in patients with atrial fibrillation and valvular heart disease: findings from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial. Circulation. 2015;132:624 632. doi: 454. Breithardt G, Baumgartner H, Berkowitz SD, Hellkamp AS, Piccini JP, Stevens SR, Lokhnygina Y, Patel MR, Halperin JL, Singer DE, et al; ROCKET AF Steering Committee & Investigators.


Breithardt G, Baumgartner H, Berkowitz SD, Hellkamp AS, Piccini JP, Stevens SR, Lokhnygina Y, Patel MR, Halperin JL, Singer DE, et al; ROCKET AF Steering Committee & Investigators. Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease par- ticipating in the ROCKET AF trial. Eur Heart J. 2014;35:3377 3385. doi: 455. P rez-G mez F, Alegr a E, Berj n J, Iriarte JA, Zumalde J, Salvador A, Mataix L; NASPEAF Investigators. Comparative effects of antiplatelet, anticoagulant, or combined therapy in patients with valvular and nonval- vular atrial fibrillation: a randomized multicenter study. J Am Coll Cardiol. 456. Ezekowitz MD, Nagarakanti R, Noack H, Brueckmann M, Litherland C, Jacobs M, Clemens A, Reilly PA, Connolly SJ, Yusuf S, et al. Comparison of dabigatran and warfarin in patients with atrial fibrillation and val- vular heart disease: the RE-LY Trial (Randomized Evaluation of Long- Term Anticoagulant Therapy). Circulation. 2016;134:589 598. doi: 457. Eikelboom JW, Connolly SJ, Brueckmann M, Granger CB, Kappetein AP, Mack MJ, Blatchford J, Devenny K, Friedman J, Guiver K, et al; RE-ALIGN Investigators. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med. 2013;369:1206 1214. doi: 458. Hering D, Piper C, Bergemann R, Hillenbach C, Dahm M, Huth C, Horstkotte D. Thromboembolic and bleeding complications following St. Jude Medical valve replacement: results of the German Experience With Low-Intensity Anticoagulation study. Chest. 2005;127:53 59. doi: 459. Massel DR, Little SH. Antiplatelet and anticoagulation for patients with prosthetic heart valves. Cochrane Database Syst Rev. 2013:CD003464. 460.


Antiplatelet and anticoagulation for patients with prosthetic heart valves. Cochrane Database Syst Rev. 2013:CD003464. 460. Garc a-Cabrera E, Fern ndez-Hidalgo N, Almirante B, Ivanova-Georgieva R, Noureddine M, Plata A, Lomas JM, G lvez-Acebal J, Hidalgo-Tenorio C, Ru z-Morales J, et al; Group for the Study of Cardiovascular Infections of the Andalusian Society of Infectious Diseases; Spanish Network for Research in Infectious Diseases. Neurological complications of infec- tive endocarditis: risk factors, outcome, and impact of cardiac surgery: a multicenter observational study. Circulation. 2013;127:2272 2284. doi: 461. Heiro M, Nikoskelainen J, Engblom E, Kotilainen E, Marttila R, Kotilainen P. Neurologic manifestations of infective endocarditis: a 17-year experience in a teaching hospital in Finland. Arch Intern Med. 2000;160:2781 2787. 462. Durante Mangoni E, Adinolfi LE, Tripodi MF, Andreana A, Gambardella M, Ragone E, Precone DF, Utili R, Ruggiero G. Risk factors for major em- bolic events in hospitalized patients with infective endocarditis. Am Heart 463. Baddour LM, Wilson WR, Bayer AS, Fowler VG Jr, Bolger AF, Levison ME, Ferrieri P, Gerber MA, Tani LY, Gewitz MH, et al; on behalf of the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease; Council on Cardiovascular Disease in the Young; Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia; American Heart Association; Infectious Diseases Society of America. Infective endocardi- tis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and CLINICAL STATEMENTS AND GUIDELINES Kleindorfer Cardiovascular Surgery and Anesthesia, American Heart Association: en- dorsed by the Infectious Diseases Society of America [published correc- tion appears in Circulation. 2005;112:2373, Circulation. 2007;115:e408, Circulation. 2007;116:e547, and Circulation. 2008;118:e497]. Circulation. 464.


2005;112:2373, Circulation. 2007;115:e408, Circulation. 2007;116:e547, and Circulation. 2008;118:e497]. Circulation. 464. Kang DH, Kim YJ, Kim SH, Sun BJ, Kim DH, Yun SC, Song JM, Choo SJ, Chung CH, Song JK, et al. Early surgery versus conventional treat- ment for infective endocarditis. N Engl J Med. 2012;366:2466 2473. doi: 465. Thuny F, Di Salvo G, Disalvo G, Belliard O, Avierinos JF, Pergola V, Rosenberg V, Casalta JP, Gouvernet J, Derumeaux G, et al. Risk of embo- lism and death in infective endocarditis: prognostic value of echocardiog- raphy: a prospective multicenter study. Circulation. 2005;112:69 75. doi: 466. Eishi K, Kawazoe K, Kuriyama Y, Kitoh Y, Kawashima Y, Omae T. Surgical management of infective endocarditis associated with cerebral complica- tions: multi-center retrospective study in Japan. J Thorac Cardiovasc Surg. 467. Barsic B, Dickerman S, Krajinovic V, Pappas P, Altclas J, Carosi G, Casab JH, Chu VH, Delahaye F, Edathodu J, et al; International Collaboration on Endocarditis Prospective Cohort Study Investigators. Influence of the timing of cardiac surgery on the outcome of patients with infec- tive endocarditis and stroke. Clin Infect Dis. 2013;56:209 217. doi: 468. John S, Walsh KM, Hui FK, Sundararajan S, Silverman S, Bain M. Dynamic angiographic nature of cerebral mycotic aneurysms in patients with infective endocarditis. Stroke. 2016;47:e8 e10. doi: 10.1161/ 469. Acar J, Iung B, Boissel JP, Samama MM, Michel PL, Teppe JP, Pony JC, Breton HL, Thomas D, Isnard R, et al. AREVA: multicenter randomized comparison of low-dose versus standard-dose anticoagulation in patients with mechanical prosthetic heart valves. Circulation. 1996;94:2107 2112. 470. M rie C, K ber L, Skov Olsen P, Andersson C, Gislason G, Skov Jensen J, Torp-Pedersen C. Association of warfarin therapy duration after bio- prosthetic aortic valve replacement with risk of mortality, thromboem- bolic complications, and bleeding. JAMA. 2012;308:2118 2125. doi: 471.


M rie C, K ber L, Skov Olsen P, Andersson C, Gislason G, Skov Jensen J, Torp-Pedersen C. Association of warfarin therapy duration after bio- prosthetic aortic valve replacement with risk of mortality, thromboem- bolic complications, and bleeding. JAMA. 2012;308:2118 2125. doi: 471. Puskas J, Gerdisch M, Nichols D, Quinn R, Anderson C, Rhenman B, Fermin L, McGrath M, Kong B, Hughes C, et al; PROACT Investigators. Reduced anticoagulation after mechanical aortic valve replacement: in- terim results from the prospective randomized On-X Valve Anticoagulation Clinical Trial randomized Food and Drug Administration investigational de- vice exemption trial. J Thorac Cardiovasc Surg. 2014;147:1202 1210. doi: 472. Torella M, Torella D, Chiodini P, Franciulli M, Romano G, De Santo L, De Feo M, Amarelli C, Sasso FC, Salvatore T, et al. LOWERing the INtensity of oral anticoaGulant Therapy in patients with bileaflet mechanical aortic valve replacement: results from the LOWERING-IT Trial. Am Heart J. 473. Whitlock RP, Sun JC, Fremes SE, Rubens FD, Teoh KH. Antithrombotic and thrombolytic therapy for valvular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 474. Barnett HJ, Boughner DR, Taylor DW, Cooper PE, Kostuk WJ, Nichol PM. Further evidence relating mitral-valve prolapse to cerebral isch- emic events. N Engl J Med. 1980;302:139 144. doi: 10.1056/ 475. Freed LA, Levy D, Levine RA, Larson MG, Evans JC, Fuller DL, Lehman B, Benjamin EJ. Prevalence and clinical outcome of mitral-valve prolapse. N Engl J Med. 1999;341:1 7. doi: 10.1056/NEJM199907013410101 476. Gilon D, Buonanno FS, Joffe MM, Leavitt M, Marshall JE, Kistler JP, Levine RA. Lack of evidence of an association between mitral-valve pro- lapse and stroke in young patients. N Engl J Med. 1999;341:8 13. doi: 477.


Lack of evidence of an association between mitral-valve pro- lapse and stroke in young patients. N Engl J Med. 1999;341:8 13. doi: 477. Orencia AJ, Petty GW, Khandheria BK, Annegers JF, Ballard DJ, Sicks JD, O Fallon WM, Whisnant JP. Risk of stroke with mitral valve pro- lapse in population-based cohort study. Stroke. 1995;26:7 13. doi: 478. Rodriguez CJ, Bartz TM, Longstreth WT Jr, Kizer JR, Barasch E, Lloyd-Jones DM, Gottdiener JS. Association of annular calcification and aortic valve sclerosis with brain findings on magnetic resonance imaging in community dwelling older adults: the Cardiovascular Health Study. J Am Coll Cardiol. 2011;57:2172 2180. doi: 10.1016/j.jacc.2011.01.034 479. Kizer JR, Wiebers DO, Whisnant JP, Galloway JM, Welty TK, Lee ET, Best LG, Resnick HE, Roman MJ, Devereux RB. Mitral annular calcification, aor- tic valve sclerosis, and incident stroke in adults free of clinical cardiovas- cular disease: the Strong Heart Study. Stroke. 2005;36:2533 2537. doi: 480. Orencia AJ, Petty GW, Khandheria BK, O Fallon WM, Whisnant JP. Mitral valve prolapse and the risk of stroke after initial cerebral ischemia. 481. Nishimura RA, McGoon MD, Shub C, Miller FA Jr, Ilstrup DM, Tajik AJ. Echocardiographically documented mitral-valve prolapse: long-term follow-up of 237 patients. N Engl J Med. 1985;313:1305 1309. doi: 482. Hayek E, Griffin B. Mitral valve prolapse: old beliefs yield to new knowl- edge. Cleve Clin J Med. 2002;69:889 896. doi: 10.3949/ccjm.69.11.889 483. Zuppiroli A, Rinaldi M, Kramer-Fox R, Favilli S, Roman MJ, Devereux RB. Natural history of mitral valve prolapse. Am J Cardiol. 1995;75:1028 484. Benjamin EJ, Plehn JF, D Agostino RB, Belanger AJ, Comai K, Fuller DL, Wolf PA, Levy D. Mitral annular calcification and the risk of stroke in an elderly cohort. N Engl J Med. 1992;327:374 379. doi: 485.


Benjamin EJ, Plehn JF, D Agostino RB, Belanger AJ, Comai K, Fuller DL, Wolf PA, Levy D. Mitral annular calcification and the risk of stroke in an elderly cohort. N Engl J Med. 1992;327:374 379. doi: 485. Kohsaka S, Jin Z, Rundek T, Boden-Albala B, Homma S, Sacco RL, Di Tullio MR. Impact of mitral annular calcification on cardiovascular events in a multiethnic community: the Northern Manhattan Study. JACC Cardiovasc 486. Roldan CA, Gelgand EA, Qualls CR, Sibbitt WL Jr. Valvular heart dis- ease as a cause of cerebrovascular disease in patients with sys- temic lupus erythematosus. Am J Cardiol. 2005;95:1441 1447. doi: 487. Khetarpal V, Mahajan N, Madhavan R, Batra S, Mopala P, Sagar A, Rapolu P, Nangia S, Afonso L. Calcific aortic valve and spontaneous em- bolic stroke: a review of literature. J Neurol Sci. 2009;287:32 35. doi: 488. Makkar RR, Fontana G, Jilaihawi H, Chakravarty T, Kofoed KF, De Backer O, Asch FM, Ruiz CE, Olsen NT, Trento A, et al. Possible subclinical leaflet thrombosis in bioprosthetic aortic valves. N Engl J Med. 2015;373:2015 489. Sundt TM, Zehr KJ, Dearani JA, Daly RC, Mullany CJ, McGregor CG, Puga FJ, Orszulak TA, Schaff HV. Is early anticoagulation with warfarin necessary after bioprosthetic aortic valve replacement? J Thorac Cardiovasc Surg. 490. Russo A, Grigioni F, Avierinos JF, Freeman WK, Suri R, Michelena H, Brown R, Sundt TM, Enriquez-Sarano M. Thromboembolic complications after surgical correction of mitral regurgitation incidence, predictors, and clinical implications. J Am Coll Cardiol. 2008;51:1203 1211. doi: 491. Colli A, Mestres CA, Castella M, Gherli T. Comparing warfarin to aspirin (WoA) after aortic valve replacement with the St. Jude Medical Epic heart valve bioprosthesis: results of the WoA Epic pilot trial. J Heart Valve Dis. 2007;16:667 671. 492.


Colli A, Mestres CA, Castella M, Gherli T. Comparing warfarin to aspirin (WoA) after aortic valve replacement with the St. Jude Medical Epic heart valve bioprosthesis: results of the WoA Epic pilot trial. J Heart Valve Dis. 2007;16:667 671. 492. Heras M, Chesebro JH, Fuster V, Penny WJ, Grill DE, Bailey KR, Danielson GK, Orszulak TA, Pluth JR, Puga FJ. High risk of thromboemboli early after bioprosthetic cardiac valve replacement. J Am Coll Cardiol. 1995;25:1111 493. Nu ez L, Gil Aguado M, Larrea JL, Celem n D, Oliver J. Prevention of thromboembolism using aspirin after mitral valve replacement with porcine bioprosthesis. Ann Thorac Surg. 1984;37:84 87. doi: 494. Meschengieser SS, Fondevila CG, Frontroth J, Santarelli MT, Lazzari MA. Low-intensity oral anticoagulation plus low-dose aspirin versus high-inten- sity oral anticoagulation alone: a randomized trial in patients with mechani- cal prosthetic heart valves. J Thorac Cardiovasc Surg. 1997;113:910 916. 495. Turpie AG, Gent M, Laupacis A, Latour Y, Gunstensen J, Basile F, Klimek M, Hirsh J. A comparison of aspirin with placebo in patients treated with war- farin after heart-valve replacement. N Engl J Med. 1993;329:524 529. 496. Goette A, Kalman JM, Aguinaga L, Akar J, Cabrera JA, Chen SA, Chugh SS, Corradi D, D Avila A, Dobrev D, et al; Document Reviewers. EHRA/HRS/ APHRS/SOLAECE expert consensus on atrial cardiomyopathies: defini- tion, characterization, and clinical implication. Europace. 2016;18:1455 497. Guichard JB, Nattel S. Atrial cardiomyopathy: a useful notion in cardiac dis- ease management or a passing fad? J Am Coll Cardiol. 2017;70:756 765. CLINICAL STATEMENTS AND GUIDELINES Kleindorfer 498. Iung B, Klein I, Mourvillier B, Olivot JM, D taint D, Longuet P, Ruimy R, Fourchy D, Laurichesse JJ, Laissy JP, et al; Study Group. Respective ef- fects of early cerebral and abdominal magnetic resonance imaging on clinical decisions in infective endocarditis.


Respective ef- fects of early cerebral and abdominal magnetic resonance imaging on clinical decisions in infective endocarditis. Eur Heart J Cardiovasc Imaging. 499. Meshaal MS, Kassem HH, Samir A, Zakaria A, Baghdady Y, Rizk HH. Impact of routine cerebral CT angiography on treatment deci- sions in infective endocarditis. PLoS One. 2015;10:e0118616. doi: 500. Stortecky S, Franzone A, Heg D, Tueller D, Noble S, Pilgrim T, Jeger R, Toggweiler S, Ferrari E, Nietlispach F, et al. Temporal trends in adoption and outcomes of transcatheter aortic valve implantation: a SwissTAVI Registry analysis. Eur Heart J Qual Care Clin Outcomes. 2019;5:242 251. doi: 501. Guerrero M, Vemulapalli S, Xiang Q, Wang DD, Eleid M, Cabalka AK, Sandhu G, Salinger M, Russell H, Greenbaum A, et al. Thirty-day out- comes of transcatheter mitral valve replacement for degenerated mi- tral bioprostheses (valve-in-valve), failed surgical rings (valve-in-ring), and native valve with severe mitral annular calcification (valve-in-mitral annular calcification) in the United States: data from the Society of Thoracic Surgeons/American College of Cardiology/Transcatheter Valve Therapy Registry. Circ Cardiovasc Interv. 2020;13:e008425. doi: 502. Dangas GD, Tijssen JGP, W hrle J, S ndergaard L, Gilard M, M llmann H, Makkar RR, Herrmann HC, Giustino G, Baldus S, et al; GALILEO Investigators. A controlled trial of rivaroxaban after transcatheter aortic-valve replacement. N Engl J Med. 2020;382:120 129. doi: 503. De Backer O, Dangas GD, Jilaihawi H, Leipsic JA, Terkelsen CJ, Makkar R, KiniAS,VeienKT,Abdel-WahabM,KimWK,etal;GALILEO-4DInvestigators. Reduced leaflet motion after transcatheter aortic-valve replacement. N Engl J Med. 2020;382:130 139. doi: 10.1056/NEJMoa1911426 504. P ss J, Desch S, Eitel C, de Waha S, Thiele H, Eitel I. Left ventricular throm- bus formation after ST-segment-elevation myocardial infarction: insights from a cardiac magnetic resonance multicenter study. Circ Cardiovasc 505.


Left ventricular throm- bus formation after ST-segment-elevation myocardial infarction: insights from a cardiac magnetic resonance multicenter study. Circ Cardiovasc 505. Phan J, Nguyen T, French J, Moses D, Schlaphoff G, Lo S, Juergens C, Dimitri H, Richards D, Thomas L. Incidence and predictors of left ven- tricular thrombus formation following acute ST-segment elevation myo- cardial infarction: a serial cardiac MRI study. Int J Cardiol Heart Vasc. 506. Vaitkus PT, Barnathan ES. Embolic potential, prevention and man- agement of mural thrombus complicating anterior myocardial infarc- tion: a meta-analysis. J Am Coll Cardiol. 1993;22:1004 1009. doi: 507. Merkler AE, Alakbarli J, Gialdini G, Navi BB, Murthy SB, Goyal P, Kim J, Devereux RB, Safford MM, Iadecola C, et al. Short-term risk of ischemic stroke after detection of left ventricular thrombus on cardiac magnetic resonance imaging. J Stroke Cerebrovasc Dis. 2019;28:1027 1031. doi: 508. Velangi PS, Choo C, Chen KA, Kazmirczak F, Nijjar PS, Farzaneh-Far A, Okasha O, Ak akaya M, Weinsaft JW, Shenoy C. Long-term embolic outcomes after detection of left ventricular thrombus by late gado- linium enhancement cardiovascular magnetic resonance imaging: a matched cohort study. Circ Cardiovasc Imaging. 2019;12:e009723. doi: 509. Fleddermann AM, Hayes CH, Magalski A, Main ML. Efficacy of direct acting oral anticoagulants in treatment of left ventricular thrombus. Am J 510. Witt BJ, Brown RD Jr, Jacobsen SJ, Weston SA, Yawn BP, Roger VL. A community-based study of stroke incidence after myocardial in- farction. Ann Intern Med. 2005;143:785 792. doi: 10.7326/0003- 511. Weinsaft JW, Kim J, Medicherla CB, Ma CL, Codella NC, Kukar N, Alaref S, Kim RJ, Devereux RB. Echocardiographic algorithm for post-myocar- dial infarction LV thrombus: a gatekeeper for thrombus evaluation by de- layed enhancement CMR. JACC Cardiovasc Imaging. 2016;9:505 515. 512.


Echocardiographic algorithm for post-myocar- dial infarction LV thrombus: a gatekeeper for thrombus evaluation by de- layed enhancement CMR. JACC Cardiovasc Imaging. 2016;9:505 515. 512. Weinsaft JW, Kim HW, Crowley AL, Klem I, Shenoy C, Van Assche L, Brosnan R, Shah DJ, Velazquez EJ, Parker M, et al. LV thrombus detection by routine echocardiography: insights into performance characteristics us- ing delayed enhancement CMR. JACC Cardiovasc Imaging. 2011;4:702 513. Robinson AA, Trankle CR, Eubanks G, Schumann C, Thompson P, Wallace RL, Gottiparthi S, Ruth B, Kramer CM, Salerno M, et al. Off-label use of direct oral anticoagulants compared with warfarin for left ventricular throm- bi. JAMA Cardiol. 2020;5:685 692. doi: 10.1001/jamacardio.2020.0652 514. Cambronero-Cortinas E, Bonanad C, Monmeneu JV, Lopez-Lereu MP, Gavara J, de Dios E, Rios C, Perez N, Racugno P, Paya A, et al. Incidence, outcomes, and predictors of ventricular thrombus after reperfused st-seg- ment-elevation myocardial infarction by using sequential cardiac MR imag- ing. Radiology. 2017;284:372 380. doi: 10.1148/radiol.2017161898 515. Leow AS, Sia CH, Tan BY, Kaur R, Yeo TC, Chan MY, Tay EL, Seet RC, Loh JP, Yeo LL. Characterisation of acute ischemic stroke in patients with left ventricular thrombi after myocardial infarction. J Thromb Thrombolysis. 516. Boyle AJ, Jorde UP, Sun B, Park SJ, Milano CA, Frazier OH, Sundareswaran KS, Farrar DJ, Russell SD; HeartMate II Clinical Investigators. Pre-operative risk factors of bleeding and stroke during left ventricular assist device sup- port: an analysis of more than 900 HeartMate II outpatients. J Am Coll 517. Frontera JA, Starling R, Cho SM, Nowacki AS, Uchino K, Hussain MS, Mountis M, Moazami N. Risk factors, mortality, and timing of ischemic and hemorrhagic stroke with left ventricular assist devices. J Heart Lung 518.


Frontera JA, Starling R, Cho SM, Nowacki AS, Uchino K, Hussain MS, Mountis M, Moazami N. Risk factors, mortality, and timing of ischemic and hemorrhagic stroke with left ventricular assist devices. J Heart Lung 518. Harvey L, Holley C, Roy SS, Eckman P, Cogswell R, Liao K, John R. Stroke after left ventricular assist device implantation: outcomes in the continuous-flow era. Ann Thorac Surg. 2015;100:535 541. doi: 519. Tsukui H, Abla A, Teuteberg JJ, McNamara DM, Mathier MA, Cadaret LM, Kormos RL. Cerebrovascular accidents in patients with a ventricu- lar assist device. J Thorac Cardiovasc Surg. 2007;134:114 123. doi: 520. John R, Naka Y, Park SJ, Sai-Sudhakar C, Salerno C, Sundareswaran KS, Farrar DJ, Milano CA. Impact of concurrent surgical valve procedures in patients receiving continuous-flow devices. J Thorac Cardiovasc Surg. 521. Aggarwal A, Gupta A, Kumar S, Baumblatt JA, Pauwaa S, Gallagher C, Treitman A, Pappas P, Tatooles A, Bhat G. Are blood stream infections associated with an increased risk of hemorrhagic stroke in patients with a left ventricular assist device? ASAIO J. 2012;58:509 513. doi: 522. Backes D, van den Bergh WM, van Duijn AL, Lahpor JR, van Dijk D, Slooter AJ. Cerebrovascular complications of left ventricular assist devices. Eur J Cardiothorac Surg. 2012;42:612 620. doi: 10.1093/ejcts/ezs320 523. Cho SM, Moazami N, Frontera JA. Stroke and intracranial hemorrhage in HeartMate II and HeartWare left ventricular assist devices: a systematic re- view. Neurocrit Care. 2017;27:17 25. doi: 10.1007/s12028-017-0386-7 524. Cleland JG, Findlay I, Jafri S, Sutton G, Falk R, Bulpitt C, Prentice C, Ford I, Trainer A, Poole-Wilson PA. The Warfarin/Aspirin Study in Heart failure (WASH): a randomized trial comparing antithrombotic strategies for patients with heart failure. Am Heart J. 2004;148:157 164. doi: 525. Cokkinos DV, Haralabopoulos GC, Kostis JB, Toutouzas PK; HELAS Investigators.


Cokkinos DV, Haralabopoulos GC, Kostis JB, Toutouzas PK; HELAS Investigators. Efficacy of antithrombotic therapy in chronic heart failure: the HELAS study. Eur J Heart Fail. 2006;8:428 432. doi: 10.1016/j. 526. Homma S, Thompson JL, Pullicino PM, Levin B, Freudenberger RS, Teerlink JR,AmmonSE,GrahamS,SaccoRL,MannDL,etal;WARCEFInvestigators. Warfarin and aspirin in patients with heart failure and sinus rhythm. N Engl J Med. 2012;366:1859 1869. doi: 10.1056/NEJMoa1202299 527. Massie BM, Collins JF, Ammon SE, Armstrong PW, Cleland JG, Ezekowitz M, Jafri SM, Krol WF, O Connor CM, Schulman KA, et al; WATCH Trial Investigators. Randomized trial of warfarin, aspirin, and clopidogrel in pa- tients with chronic heart failure: the Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) trial. Circulation. 2009;119:1616 1624. 528. Zannad F, Anker SD, Byra WM, Cleland JGF, Fu M, Gheorghiade M, Lam CSP, Mehra MR, Neaton JD, Nessel CC, et al; COMMANDER HF Investigators. Rivaroxaban in patients with heart failure, sinus rhythm, and coronary disease. N Engl J Med. 2018;379:1332 1342. doi: 529. Andreas M, Moayedifar R, Wieselthaler G, Wolzt M, Riebandt J, Haberl T, Angleitner P, Schloglhofer T, Wiedemann D, Schima H, et al. Increased thromboembolic events with dabigatran compared with vi- tamin K antagonism in left ventricular assist device patients: a ran- domized controlled pilot trial. Circ Heart Fail. 2017;10:e003709. doi: 530. Wada H, Yasu T, Sakakura K, Hayakawa Y, Ishida T, Kobayashi N, Kubo N, Ako J, Momomura S. Contrast echocardiography for the diagnosis of CLINICAL STATEMENTS AND GUIDELINES Kleindorfer left ventricular thrombus in anterior myocardial infarction. Heart Vessels. 531. Meurin P, Brandao Carreira V, Dumaine R, Shqueir A, Milleron O, Safar B, Perna S, Smadja C, Genest M, Garot J, et al; College National des Cardiologues Fran ais; Coll ge National des Cardiologues des H pitaux Fran ais, Paris, France.


Meurin P, Brandao Carreira V, Dumaine R, Shqueir A, Milleron O, Safar B, Perna S, Smadja C, Genest M, Garot J, et al; College National des Cardiologues Fran ais; Coll ge National des Cardiologues des H pitaux Fran ais, Paris, France. Incidence, diagnostic methods, and evolution of left ventricular thrombus in patients with anterior myocardial infarction and low left ventricular ejection fraction: a prospective multicenter study. Am Heart 532. Roifman I, Connelly KA, Wright GA, Wijeysundera HC. Echocardiography vs. cardiac magnetic resonance imaging for the diagnosis of left ventricu- lar thrombus: a systematic review. Can J Cardiol. 2015;31:785 791. doi: 533. Muser D, Nucifora G, Gianfagna E, Pavoni D, Rebellato L, Facchin D, Daleffe E, Proclemer A. Clinical spectrum of isolated left ventricular non- compaction: thromboembolic events, malignant left ventricular arrhyth- mias, and refractory heart failure. J Am Coll Cardiol. 2014;63:e39. doi: 534. Oechslin EN, Attenhofer Jost CH, Rojas JR, Kaufmann PA, Jenni R. Long-term follow-up of 34 adults with isolated left ventricular noncom- paction: a distinct cardiomyopathy with poor prognosis. J Am Coll Cardiol. 535. St llberger C, Blazek G, Dobias C, Hanafin A, Wegner C, Finsterer J. Frequency of stroke and embolism in left ventricular hypertrabecu- lation/noncompaction. Am J Cardiol. 2011;108:1021 1023. doi: 536. Feldman D, Pamboukian SV, Teuteberg JJ, Birks E, Lietz K, Moore SA, Morgan JA, Arabia F, Bauman ME, Buchholz HW, et al; International Society for Heart and Lung Transplantation. The 2013 International Society for Heart and Lung Transplantation guidelines for mechanical circulatory sup- port: executive summary. J Heart Lung Transplant. 2013;32:157 187. doi: 537. Lee JM, Park JJ, Jung HW, Cho YS, Oh IY, Yoon CH, Suh JW, Chun EJ, Choi SI, Youn TJ, et al. Left ventricular thrombus and subsequent thrombo- embolism, comparison of anticoagulation, surgical removal, and antiplatelet agents. J Atheroscler Thromb.


Left ventricular thrombus and subsequent thrombo- embolism, comparison of anticoagulation, surgical removal, and antiplatelet agents. J Atheroscler Thromb. 2013;20:73 93. doi: 10.5551/jat.13540 538. Lanzillo C, Di Roma M, Sciahbasi A, Minati M, Maresca L, Pendenza G, Romagnoli E, Summaria F, Patrizi R, Di Luozzo M, et al. Cardiac mag- netic resonance detection of left ventricular thrombus in acute myo- cardial infarction. Acute Card Care. 2013;15:11 16. doi: 10.3109/ 539. Johannessen KA, Nordrehaug JE, von der Lippe G. Left ventricular thrombi after short-term high-dose anticoagulants in acute myocardial infarction. Eur Heart J. 1987;8:975 980. doi: 10.1093/oxfordjournals.eurheartj.a062374 540. Kolekar S, Munjewar C, Sharma S. Dabigatran for left ventricular thrombus. Indian Heart J. 2015;67:495 496. doi: 10.1016/j.ihj.2015.06.010 541. Chung K, Paek YM, Lee HJ, Hong KS. Dabigatran effect on left ventricular thrombus in a patient with acute ischemic stroke. J Stroke. 2015;17:366 542. Ohashi N, Okada T, Uchida M, Amioka M, Fujiwara M, Kaseda S. Effects of dabigatran on the resolution of left ventricular thrombus af- ter acute myocardial infarction. Intern Med. 2015;54:1761 1763. doi: 543. Nagamoto Y, Shiomi T, Matsuura T, Okahara A, Takegami K, Mine D, Shirahama T, Koga Y, Yoshida K, Sadamatsu K, et al. Resolution of a left ventricular thrombus by the thrombolytic action of dabigatran. Heart 544. Nakasuka K, Ito S, Noda T, Hasuo T, Sekimoto S, Ohmori H, Inomata M, Yoshida T, Tamai N, Saeki T, et al. Resolution of left ventricular thrombus secondary to tachycardia-induced heart failure with rivaroxaban. Case Rep E, Torres Llergo J, Lozano Cabezas C, Fern ndez Guerrero JC. Resolution of left ventricular thrombus by rivaroxaban. Future Cardiol. 2014;10:333 546. Mano Y, Koide K, Sukegawa H, Kodaira M, Ohki T. Successful resolu- tion of a left ventricular thrombus with apixaban treatment following acute myocardial infarction. Heart Vessels. 2016;31:118 123. doi: 547.


Mano Y, Koide K, Sukegawa H, Kodaira M, Ohki T. Successful resolu- tion of a left ventricular thrombus with apixaban treatment following acute myocardial infarction. Heart Vessels. 2016;31:118 123. doi: 547. Jenni R, Oechslin E, Schneider J, Attenhofer Jost C, Kaufmann PA. Echocardiographic and pathoanatomical characteristics of isolated left ventricular non-compaction: a step towards classification as a distinct car- diomyopathy. Heart. 2001;86:666 671. doi: 10.1136/heart.86.6.666 548. Ross SB, Jones K, Blanch B, Puranik R, McGeechan K, Barratt A, Semsarian C. A systematic review and meta-analysis of the prevalence of left ventricular non-compaction in adults. Eur Heart J. 2020;41:1428 549. Ritter M, Oechslin E, S tsch G, Attenhofer C, Schneider J, Jenni R. Isolated noncompaction of the myocardium in adults. Mayo Clin Proc. 1997;72:26 550. Di Tullio MR, Qian M, Thompson JL, Labovitz AJ, Mann DL, Sacco RL, Pullicino PM, Freudenberger RS, Teerlink JR, Graham S, et al; WARCEF Investigators. Left ventricular ejection fraction and risk of stroke and cardiac events in heart failure: data from the Warfarin Versus Aspirin in Reduced Ejection Fraction trial. Stroke. 2016;47:2031 2037. doi: 551. Meurin P, Tabet JY, Renaud N, Weber H, Grosdemouge A, Bourmayan C, Driss AB. Treatment of left ventricular thrombi with a low molecular weight heparin. Int J Cardiol. 2005;98:319 323. doi: 10.1016/j.ijcard. 552. Kent DM, Dahabreh IJ, Ruthazer R, Furlan AJ, Reisman M, Carroll JD, Saver JL, Smalling RW, J ni P, Mattle HP, et al. Device closure of patent foramen ovale after stroke: pooled analysis of completed ran- domized trials. J Am Coll Cardiol. 2016;67:907 917. doi: 10.1016/j. 553. Lee PH, Song JK, Kim JS, Heo R, Lee S, Kim DH, Song JM, Kang DH, Kwon SU, Kang DW, et al. Cryptogenic stroke and high-risk patent foramen ovale: the DEFENSE-PFO trial. J Am Coll Cardiol. 2018;71:2335 2342. 554.


Cryptogenic stroke and high-risk patent foramen ovale: the DEFENSE-PFO trial. J Am Coll Cardiol. 2018;71:2335 2342. 554. Mas JL, Derumeaux G, Guillon B, Massardier E, Hosseini H, Mechtouff L, Arquizan C, B jot Y, Vuillier F, Detante O, et al; CLOSE Investigators. Patent foramen ovale closure or anticoagulation vs. antiplatelets after stroke. N Engl J Med. 2017;377:1011 1021. doi: 10.1056/NEJMoa1705915 555. Saver JL, Carroll JD, Thaler DE, Smalling RW, MacDonald LA, Marks DS, Tirschwell DL; RESPECT Investigators. Long-term outcomes of pat- ent foramen ovale closure or medical therapy after stroke. N Engl J Med. 556. S ndergaard L, Kasner SE, Rhodes JF, Andersen G, Iversen HK, Nielsen-Kudsk JE, Settergren M, Sj strand C, Roine RO, Hildick-Smith D, et al; Gore REDUCE Clinical Study Investigators. Patent foramen ova- le closure or antiplatelet therapy for cryptogenic stroke. N Engl J Med. 557. Turc G, Lee JY, Brochet E, Kim JS, Song JK, Mas JL; CLOSE and DEFENSE-PFO Trial Investigators. Atrial septal aneurysm, shunt size, and recurrent stroke risk in patients with patent foramen ovale. J Am Coll 558. Carroll JD, Saver JL, Thaler DE, Smalling RW, Berry S, MacDonald LA, Marks DS, Tirschwell DL; RESPECT Investigators. Closure of patent fora- men ovale versus medical therapy after cryptogenic stroke. N Engl J Med. 559. Furlan AJ, Reisman M, Massaro J, Mauri L, Adams H, Albers GW, Felberg R, Herrmann H, Kar S, Landzberg M, et al; CLOSURE I Investigators. Closure or medical therapy for cryptogenic stroke with patent foramen ovale. N Engl J Med. 2012;366:991 999. doi: 10.1056/NEJMoa1009639 560. Meier B, Kalesan B, Mattle HP, Khattab AA, Hildick-Smith D, Dudek D, Andersen G, Ibrahim R, Schuler G, Walton AS, et al; PC Trial Investigators. Percutaneous closure of patent foramen ovale in crypto- genic embolism. N Engl J Med. 2013;368:1083 1091. doi: 10.1056/ 561.


Percutaneous closure of patent foramen ovale in crypto- genic embolism. N Engl J Med. 2013;368:1083 1091. doi: 10.1056/ 561. Turc G, Calvet D, Guerin P, Sroussi M, Chatellier G, Mas JL; CLOSE Investigators. Closure, anticoagulation, or antiplatelet therapy for crypto- genic stroke with patent foramen ovale: systematic review of randomized trials, sequential meta-analysis, and new insights from the CLOSE study. J Am Heart Assoc. 2018;7:e008356. doi: 10.1161/JAHA.117.008356 562. Merkler AE, Gialdini G, Yaghi S, Okin PM, Iadecola C, Navi BB, Kamel H. Safety outcomes after percutaneous transcatheter closure of pat- ent foramen ovale. Stroke. 2017;48:3073 3077. doi: 10.1161/ 563. Mas JL, Derex L, Gu rin P, Guillon B, Habib G, Juliard JM, Marijon E, Massardier E, Meneveau N, Vuillier F. Transcatheter closure of patent fora- men ovale to prevent stroke recurrence in patients with otherwise unex- plained ischaemic stroke: expert consensus of the French Neurovascular Society and the French Society of Cardiology. Arch Cardiovasc Dis. 564. Pristipino C, Sievert H, D Ascenzo F, Louis Mas J, Meier B, Scacciatella P, Hildick-Smith D, Gaita F, Toni D, Kyrle P, et al; Evidence Synthesis Team; EAPCI Scientific Documents and Initiatives Committee; International Experts. European position paper on the management of patients with pat- ent foramen ovale. General approach and left circulation thromboembolism. Eur Heart J. 2019;40:3182 3195. doi: 10.1093/eurheartj/ehy649 CLINICAL STATEMENTS AND GUIDELINES Kleindorfer 565. Kamel H, Merkler AE, Iadecola C, Gupta A, Navi BB. Tailoring the ap- proach to embolic stroke of undetermined source: a review. JAMA Neurol. 566. Kent DM, Ruthazer R, Weimar C, Mas JL, Serena J, Homma S, Di Angelantonio E, Di Tullio MR, Lutz JS, Elkind MS, et al. An index to identify stroke-related vs incidental patent foramen ovale in cryp- togenic stroke. Neurology. 2013;81:619 625. doi: 10.1212/WNL. 567.


An index to identify stroke-related vs incidental patent foramen ovale in cryp- togenic stroke. Neurology. 2013;81:619 625. doi: 10.1212/WNL. 567. Kuijpers T, Spencer FA, Siemieniuk RAC, Vandvik PO, Otto CM, Lytvyn L, Mir H, Jin AY, Manja V, Karthikeyan G, et al. Patent foramen ovale closure, antiplatelet therapy or anticoagulation therapy alone for management of cryptogenic stroke? A clinical practice guideline. BMJ. 2018;362:k2515. 568. Kent DM, Saver JL, Ruthazer R, Furlan AJ, Reisman M, Carroll JD, Smalling RW, J ni P, Mattle HP, Meier B, et al. Risk of Paradoxical Embolism (RoPE)- estimated attributable fraction correlates with the benefit of patent fora- men ovale closure: an analysis of 3 trials. Stroke. 2020;51:3119 3123. 569. Mazzucco S, Li L, Rothwell PM. Prognosis of cryptogenic stroke with pat- ent foramen ovale at older ages and implications for trials: a population- based study and systematic review. JAMA Neurol. 2020;77:1 9. doi: 570. Deng W, Yin S, McMullin D, Inglessis-Azuaje I, Elmariah S, Hung J, Lo EH, Palacios IF, Buonanno FS, Ning M. Residual shunt after patent fo- ramen ovale closure and long-term stroke recurrence. Ann Intern Med. 571. Mess SR, Gronseth GS, Kent DM, Kizer JR, Homma S, Rosterman L, Carroll JD, Ishida K, Sangha N, Kasner SE. Practice advisory update summary: patent foramen ovale and secondary stroke prevention: report of the Guideline Subcommittee of the American Academy of Neurology. 572. Seipelt RG, Franke A, Vazquez-Jimenez JF, Hanrath P, von Bernuth G, Messmer BJ, M hler EG. Thromboembolic complications after Fontan procedures: comparison of different therapeutic approaches. Ann Thorac 573. Monagle P, Cochrane A, Roberts R, Manlhiot C, Weintraub R, Szechtman B, Hughes M, Andrew M, McCrindle BW; Fontan Anticoagulation Study Group. A multicenter, randomized trial comparing heparin/warfarin and acetylsalicylic acid as primary thromboprophylaxis for 2 years after the Fontan procedure in children.


A multicenter, randomized trial comparing heparin/warfarin and acetylsalicylic acid as primary thromboprophylaxis for 2 years after the Fontan procedure in children. J Am Coll Cardiol. 2011;58:645 651. doi: 574. Lanz J, Brophy JM, Therrien J, Kaouache M, Guo L, Marelli AJ. Stroke in adults with congenital heart disease: incidence, cumulative risk, and predictors. Circulation. 2015;132:2385 2394. doi: 10.1161/ 575. Mandalenakis Z, Rosengren A, Lappas G, Eriksson P, Hansson PO, Dellborg M. Ischemic stroke in children and young adults with congeni- tal heart disease. J Am Heart Assoc. 2016;5:e003071. doi: 10.1161/ 576. Hoffmann A, Chockalingam P, Balint OH, Dadashev A, Dimopoulos K, Engel R, Schmid M, Schwerzmann M, Gatzoulis MA, Mulder B, et al. Cerebrovascular accidents in adult patients with congenital heart disease. 577. Nattel SN, Adrianzen L, Kessler EC, Andelfinger G, Dehaes M, C t -Corriveau G, Trelles MP. Congenital heart disease and neurodevelop- ment: clinical manifestations, genetics, mechanisms, and implications. Can J Cardiol. 2017;33:1543 1555. doi: 10.1016/j.cjca.2017.09.020 578. Hebson CL, McCabe NM, Elder RW, Mahle WT, McConnell M, Kogon BE, Veledar E, Jokhadar M, Vincent RN, Sahu A, et al. Hemodynamic phenotype of the failing Fontan in an adult population. Am J Cardiol. 2013;112:1943 579. Triedman JK. Arrhythmias in adults with congenital heart disease. Heart. 580. de Groot NM, Atary JZ, Blom NA, Schalij MJ. Long-term outcome af- ter ablative therapy of postoperative atrial tachyarrhythmia in patients with congenital heart disease and characteristics of atrial tachyarrhyth- mia recurrences. Circ Arrhythm Electrophysiol. 2010;3:148 154. doi: 581. McRae ME. Long-term issues after the Fontan procedure. AACN Adv Crit 582. Georgekutty J, Kazerouninia A, Wang Y, Ermis PR, Parekh DR, Franklin WJ, Lam WW. Novel oral anticoagulant use in adult Fontan patients: a single center experience. Congenit Heart Dis. 2018;13:541 547. doi: 583.


Novel oral anticoagulant use in adult Fontan patients: a single center experience. Congenit Heart Dis. 2018;13:541 547. doi: 583. Yang H, Bouma BJ, Mulder BJM; Non vitamin K antagonist Oral anti- coagulants for ThromboEmbolic prevention in adult congenital heart disease (NOTE) Investigators. Is initiating NOACs for atrial arrhythmias safe in adults with congenital heart disease? Cardiovasc Drugs Ther. 584. Rychik J, Atz AM, Celermajer DS, Deal BJ, Gatzoulis MA, Gewillig MH, Hsia T-Y, Hsu DT, Kovacs AH, McCrindle BW, et al; on behalf of the American Heart Association Council on Cardiovascular Disease in the Young and Council on Cardiovascular and Stroke Nursing. Evaluation and manage- ment of the child and adult with Fontan circulation: a scientific statement from the American Heart Association. Circulation. 2019;140:e234 e284. 585. Goff DA, Blume ED, Gauvreau K, Mayer JE, Lock JE, Jenkins KJ. Clinical outcome of fenestrated Fontan patients after closure: the first 10 years. 585a. International Society for Adult Congenital Heart Disease. NOTE Registry. Accessed December 1, 2019. http://www.isachd.org/content/note-registry 586. Elbardissi AW, Dearani JA, Daly RC, Mullany CJ, Orszulak TA, Puga FJ, Schaff HV. Embolic potential of cardiac tumors and outcome af- ter resection: a case-control study. Stroke. 2009;40:156 162. doi: 587. Grinda JM, Couetil JP, Chauvaud S, D Attellis N, Berrebi A, Fabiani JN, Deloche A, Carpentier A. Cardiac valve papillary fibroelastoma: surgical excision for revealed or potential embolization. J Thorac Cardiovasc Surg. 588. Gowda RM, Khan IA, Nair CK, Mehta NJ, Vasavada BC, Sacchi TJ. Cardiac papillary fibroelastoma: a comprehensive analysis of 725 cases. Am Heart 589. Reynen K. Frequency of primary tumors of the heart. Am J Cardiol. 590. Lai MM, Li TC, Lin CL, Sung FC, Lin CC, Liu CS, Kao CH. Benign neoplasm of the heart increases the risk of first ischemic stroke: a population-based cohort study.


Benign neoplasm of the heart increases the risk of first ischemic stroke: a population-based cohort study. Int J Stroke. 2015;10:202 206. doi: 10.1111/ijs.12314 591. Valente M, Basso C, Thiene G, Bressan M, Stritoni P, Cocco P, Fasoli G. Fibroelastic papilloma: a not-so-benign cardiac tumor. Cardiovasc Pathol. 592. Tamin SS, Maleszewski JJ, Scott CG, Khan SK, Edwards WD, Bruce CJ, Oh JK, Pellikka PA, Klarich KW. Prognostic and bioepidemiologic implications of papillary fibroelastomas. J Am Coll Cardiol. 2015;65:2420 2429. doi: 593. Markus HS, Hayter E, Levi C, Feldman A, Venables G, Norris J. Antiplatelet treatment compared with anticoagulation treatment for cervical artery dis- section (CADISS): a randomised trial. Lancet Neurol. 2015;14:361 367. 594. Markus HS, Levi C, King A, Madigan J, Norris J; Cervical Artery Dissection in Stroke Study (CADISS) Investigators. Antiplatelet therapy vs anticoagu- lation therapy in cervical artery dissection: the Cervical Artery Dissection in Stroke Study (CADISS) randomized clinical trial final results. JAMA Neurol. 595. Moon K, Albuquerque FC, Cole T, Gross BA, McDougall CG. Stroke prevention by endovascular treatment of carotid and vertebral ar- tery dissections. J Neurointerv Surg. 2017;9:952 957. doi: 10.1136/ 596. Spanos K, Karathanos C, Stamoulis K, Giannoukas AD. Endovascular treatment of traumatic internal carotid artery pseudoaneurysm. Injury. 597. Redekop GJ. Extracranial carotid and vertebral artery dissection: a review. Can J Neurol Sci. 2008;35:146 152. doi: 10.1017/s0317167100008556 598. Morel A, Naggara O, Touz E, Raymond J, Mas JL, Meder JF, Oppenheim C. Mechanism of ischemic infarct in spontaneous cervical artery dissection. 599. Weimar C, Kraywinkel K, Hagemeister C, Haass A, Katsarava Z, Brunner F, Haverkamp C, Schmid E, Diener HC; German Stroke Study Collaboration. Recurrent stroke after cervical artery dissection. J Neurol Neurosurg 600. Vossen CY, Rosendaal FR; EPCOT Study Group. Risk of arterial thrombo- sis in carriers of familial thrombophilia. J Thromb Haemost.


Risk of arterial thrombo- sis in carriers of familial thrombophilia. J Thromb Haemost. 2006;4:916 of protein C or protein S confers increased risk of arterial thromboembolic events at a young age: results from a large family cohort study. Circulation. 602. Kenet G, L tkhoff LK, Albisetti M, Bernard T, Bonduel M, Brandao L, Chabrier S, Chan A, deVeber G, Fiedler B, et al. Impact of CLINICAL STATEMENTS AND GUIDELINES Kleindorfer thrombophilia on risk of arterial ischemic stroke or cerebral sinovenous thrombosis in neonates and children: a systematic review and meta- analysis of observational studies. Circulation. 2010;121:1838 1847. doi: 603. Pezzini A, Grassi M, Zotto ED, Giossi A, Volonghi I, Costa P, Grau A, Magoni M, Padovani A, Lichy C. Do common prothrombotic mutations influence the risk of cerebral ischaemia in patients with patent foramen ovale? Systematic review and meta-analysis. Thromb Haemost. 2009;101:813 817. 604. Schellekens MMI, van Alebeek ME, Arntz RM, Synhaeve NE, Maaijwee NAMM, Schoonderwaldt HC, van der Vlugt MJ, van Dijk EJ, Rutten-Jacobs LCA, de Leeuw FE. Prothrombotic factors do not increase the risk of recurrent ischemic events after cryptogenic stroke at young age: the FUTURE study. J Thromb Thrombolysis. 2018;45:504 511. doi: 605. Chiasakul T, De Jesus E, Tong J, Chen Y, Crowther M, Garcia D, Chai-Adisaksopha C, Mess SR, Cuker A. Inherited thrombophilia and the risk of arterial ischemic stroke: a systematic review and meta-analysis. J Am Heart Assoc. 2019;8:e012877. doi: 10.1161/JAHA.119.012877 606. Mazzolai L, Aboyans V, Ageno W, Agnelli G, Alatri A, Bauersachs R, Brekelmans MPA, B ller HR, Elias A, Farge D, et al. Diagnosis and man- agement of acute deep vein thrombosis: a joint consensus document from the European Society of Cardiology working groups of aorta and peripheral vascular diseases and pulmonary circulation and right ventricular function. Eur Heart J.


Diagnosis and man- agement of acute deep vein thrombosis: a joint consensus document from the European Society of Cardiology working groups of aorta and peripheral vascular diseases and pulmonary circulation and right ventricular function. Eur Heart J. 2018;39:4208 4218. doi: 10.1093/eurheartj/ehx003 607. Folsom AR, Rosamond WD, Shahar E, Cooper LS, Aleksic N, Nieto FJ, Rasmussen ML, Wu KK. Prospective study of markers of hemostatic func- tion with risk of ischemic stroke: the Atherosclerosis Risk in Communities (ARIC) Study Investigators. Circulation. 1999;100:736 742. doi: 608. Zakai NA, Judd SE, Kissela B, Howard G, Safford MM, Cushman M. Factor VIII, protein C and cardiovascular disease risk: the REasons for Geographic and Racial Differences in Stroke Study (REGARDS). Thromb Haemost. 609. Nakashima MO, Rogers HJ. Hypercoagulable states: an algorithmic ap- proach to laboratory testing and update on monitoring of direct oral antico- agulants. Blood Res. 2014;49:85 94. doi: 10.5045/br.2014.49.2.85 610. Gouse BM, Boehme AK, Monlezun DJ, Siegler JE, George AJ, Brag K, Albright KC, Beasley TM, Leissinger C, El Khoury R, et al. New thrombotic events in ischemic stroke patients with elevated factor VIII. Thrombosis. 611. Raffield LM, Lu AT, Szeto MD, Little A, Grinde KE, Shaw J, Auer PL, Cushman M, Horvath S, Irvin MR, et al; NHLBI Trans-Omics for Precision Medicine (TOPMed) Consortium, TOPMed Hematology & Hemostasis Working Group. Coagulation factor VIII: Relationship to cardiovascular disease risk and whole genome sequence and epigenome-wide analy- sis in African Americans. J Thromb Haemost. 2020;18:1335 1347. doi: 612. Levine SR, Brey RL, Tilley BC, Thompson JL, Sacco RL, Sciacca RR, Murphy A, Lu Y, Costigan TM, Rhine C, et al; APASS Investigators. Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA. 2004;291:576 584. doi: 613.


Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA. 2004;291:576 584. doi: 613. Finazzi G, Marchioli R, Brancaccio V, Schinco P, Wisloff F, Musial J, Baudo F, Berrettini M, Testa S, D Angelo A, et al. A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphos- pholipid syndrome (WAPS). J Thromb Haemost. 2005;3:848 853. doi: 614. Crowther MA, Ginsberg JS, Julian J, Denburg J, Hirsh J, Douketis J, Laskin C, Fortin P, Anderson D, Kearon C, et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the an- tiphospholipid antibody syndrome. N Engl J Med. 2003;349:1133 1138. 615. Okuma H, Kitagawa Y, Yasuda T, Tokuoka K, Takagi S. Comparison be- tween single antiplatelet therapy and combination of antiplatelet and anticoagulation therapy for secondary prevention in ischemic stroke pa- tients with antiphospholipid syndrome. Int J Med Sci. 2009;7:15 18. doi: 616. Pengo V, Denas G, Zoppellaro G, Jose SP, Hoxha A, Ruffatti A, Andreoli L, Tincani A, Cenci C, Prisco D, et al. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood. 2018;132:1365 1371. 617. Ordi-Ros J, S ez-Comet L, P rez-Conesa M, Vidal X, Riera-Mestre A, Castro-Salom A, Cuquet-Pedragosa J, Ortiz-Santamaria V, Mauri-Plana M, Sol C, et al. Rivaroxaban versus vitamin K antagonist in antiphospho- lipid syndrome: a randomized noninferiority trial. Ann Intern Med. 2019; 618. Dufrost V, Risse J, Reshetnyak T, Satybaldyeva M, Du Y, Yan XX, Salta S, Gerotziafas G, Jing ZC, Elalamy I, et al. Increased risk of thrombosis in antiphospholipid syndrome patients treated with direct oral anticoagulants: results from an international patient-level data meta-analysis. Autoimmun 619.


Increased risk of thrombosis in antiphospholipid syndrome patients treated with direct oral anticoagulants: results from an international patient-level data meta-analysis. Autoimmun 619. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, Derksen RH, DE Groot PG, Koike T, Meroni PL, et al. International con- sensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4:295 306. 620. Andreoli L, Chighizola CB, Banzato A, Pons-Estel GJ, Ramire de Jesus G, Erkan D. Estimated frequency of antiphospholipid antibodies in patients with pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis: a critical review of the literature. Arthritis Care Res (Hoboken). 621. Cervera R, Piette JC, Font J, Khamashta MA, Shoenfeld Y, Camps MT, Jacobsen S, Lakos G, Tincani A, Kontopoulou-Griva I, et al; Euro- Phospholipid Project Group. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum. 2002;46:1019 1027. doi: 622. Nojima J, Kuratsune H, Suehisa E, Kitani T, Iwatani Y, Kanakura Y. Strong correlation between the prevalence of cerebral infarction and the pres- ence of anti-cardiolipin/beta2-glycoprotein I and anti-phosphatidylserine/ prothrombin antibodies: co-existence of these antibodies enhances ADP- induced platelet activation in vitro. Thromb Haemost. 2004;91:967 976. 623. Tektonidou MG, Andreoli L, Limper M, Amoura Z, Cervera R, Costedoat- Chalumeau N, Cuadrado MJ, D rner T, Ferrer-Oliveras R, Hambly K, et al. EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis. 2019;78:1296 1304. doi: 10.1136/ 624. Woller SC, Stevens SM, Kaplan DA, Branch DW, Aston VT, Wilson EL, Gallo HM, Johnson EG, Rondina MT, Lloyd JF, et al. Apixaban for the Secondary Prevention of Thrombosis Among Patients With Antiphospholipid Syndrome: study rationale and design (ASTRO-APS). Clin Appl Thromb 625. VITATOPS Trial Study Group.


Apixaban for the Secondary Prevention of Thrombosis Among Patients With Antiphospholipid Syndrome: study rationale and design (ASTRO-APS). Clin Appl Thromb 625. VITATOPS Trial Study Group. B vitamins in patients with recent transient ischaemic attack or stroke in the VITAmins TO Prevent Stroke (VITATOPS) trial: a randomised, double-blind, parallel, placebo-controlled trial. Lancet 626. Toole JF, Malinow MR, Chambless LE, Spence JD, Pettigrew LC, Howard VJ, Sides EG, Wang CH, Stampfer M. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA. 2004;291:565 575. doi: 10.1001/jama.291.5.565 627. Galan P, Kesse-Guyot E, Czernichow S, Briancon S, Blacher J, Hercberg S; SU.FOL.OM3 Collaborative Group. Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: a randomised placebo controlled trial. BMJ. 2010;341:c6273. doi: 10.1136/bmj.c6273 628. Lonn E, Yusuf S, Arnold MJ, Sheridan P, Pogue J, Micks M, McQueen MJ, Probstfield J, Fodor G, Held C, Euro-Phospholipid; Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators. Homocysteine lower- ing with folic acid and B vitamins in vascular disease. N Engl J Med. 629. Hsu CY, Chiu SW, Hong KS, Saver JL, Wu YL, Lee JD, Lee M, Ovbiagele B. Folic acid in stroke prevention in countries without mandatory folic acid food fortification: a meta-analysis of randomized controlled trials. J Stroke. 630. Li Y, Huang T, Zheng Y, Muka T, Troup J, Hu FB. Folic acid supplemen- tation and the risk of cardiovascular diseases: a meta-analysis of ran- domized controlled trials. J Am Heart Assoc. 2016;5:e003768. doi: 631. Mart -Carvajal AJ, Sol I, Lathyris D, Dayer M. Homocysteine-lowering in- terventions for preventing cardiovascular events. Cochrane Database Syst 632. Park JH, Saposnik G, Ovbiagele B, Markovic D, Towfighi A.


Park JH, Saposnik G, Ovbiagele B, Markovic D, Towfighi A. Effect of B-vitamins on stroke risk among individuals with vascular disease who are not on antiplatelets: a meta-analysis. Int J Stroke. 2016;11:206 211. doi: 633. Spence JD, Yi Q, Hankey GJ. B vitamins in stroke prevention: time to reconsider. Lancet Neurol. 2017;16:750 760. doi: 10.1016/S1474- CLINICAL STATEMENTS AND GUIDELINES Kleindorfer 634. Tian T, Yang KQ, Cui JG, Zhou LL, Zhou XL. Folic acid supplementation for stroke prevention in patients with cardiovascular disease. Am J Med Sci. 635. Zeng R, Xu CH, Xu YN, Wang YL, Wang M. The effect of folate fortifica- tion on folic acid-based homocysteine-lowering intervention and stroke risk: a meta-analysis. Public Health Nutr. 2015;18:1514 1521. doi: 636. Zhao M, Wu G, Li Y, Wang X, Hou FF, Xu X, Qin X, Cai Y. Meta- analysis of folic acid efficacy trials in stroke prevention: in- sight into effect modifiers. Neurology. 2017;88:1830 1838. doi: 637. Zhao M, Wang X, He M, Qin X, Tang G, Huo Y, Li J, Fu J, Huang X, Cheng X, et al. Homocysteine and stroke risk: modifying effect of methylenetet- rahydrofolate reductase C677T polymorphism and folic acid intervention. 638. Etminan M, Takkouche B, Isorna FC, Samii A. Risk of ischaemic stroke in people with migraine: systematic review and meta-analysis of observa- tional studies. BMJ. 2005;330:63. doi: 10.1136/bmj.38302.504063.8F 639. Bashir A, Lipton RB, Ashina S, Ashina M. Migraine and structural changes in the brain: a systematic review and meta-analysis. Neurology. 640. Serrano F, Arauz A, Uribe R, Becerra LC, Mantilla K, Zerme o F. Long-term follow-up of patients with migrainous infarction. Clin Neurol Neurosurg. 641. Hoekstra-van Dalen RA, Cillessen JP, Kappelle LJ, van Gijn J. Cerebral infarcts associated with migraine: clinical features, risk factors and follow- up. J Neurol. 1996;243:511 515. doi: 10.1007/BF00886872 642.


Hoekstra-van Dalen RA, Cillessen JP, Kappelle LJ, van Gijn J. Cerebral infarcts associated with migraine: clinical features, risk factors and follow- up. J Neurol. 1996;243:511 515. doi: 10.1007/BF00886872 642. Rothrock J, North J, Madden K, Lyden P, Fleck P, Dittrich H. Migraine and migrainous stroke: risk factors and prognosis. Neurology. 1993;43:2473 643. Kellner-Weldon F, El-Koussy M, Jung S, Jossen M, Klinger-Gratz PP, Wiest R. Cerebellar hypoperfusion in migraine attack: incidence and significance. AJNR Am J Neuroradiol. 2018;39:435 440. doi: 10.3174/ajnr.A5508 644. Sheikh HU, Pavlovic J, Loder E, Burch R. Risk of stroke associated with use of estrogen containing contraceptives in women with migraine: a sys- tematic review. Headache. 2018;58:5 21. doi: 10.1111/head.13229 645. Roberto G, Raschi E, Piccinni C, Conti V, Vignatelli L, D Alessandro R, De Ponti F, Poluzzi E. Adverse cardiovascular events associated with triptans and ergotamines for treatment of migraine: systematic re- view of observational studies. Cephalalgia. 2015;35:118 131. doi: 646. Aradi S, Kaiser E, Cucchiara B. Ischemic stroke associated with cal- citonin gene-related peptide inhibitor therapy for migraine: a case re- port. J Stroke Cerebrovasc Dis. 2019;28:104286. doi: 10.1016/j. 647. Chen ST, Hellkamp AS, Becker RC, Berkowitz SD, Breithardt G, Fox KAA, Hacke W, Halperin JL, Hankey GJ, Mahaffey KW, et al. Efficacy and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and a history of cancer: observations from ROCKET AF. Eur Heart J Qual Care Clin Outcomes. 2019;5:145 152. doi: 10.1093/ehjqcco/qcy040 648. Melloni C, Dunning A, Granger CB, Thomas L, Khouri MG, Garcia DA, Hylek EM, Hanna M, Wallentin L, Gersh BJ, et al. Efficacy and safety of apixaban versus warfarin in patients with atrial fibrillation and a history of cancer: insights from the ARISTOTLE Trial. Am J Med. 2017;130:1440 1448.e1. 649.


Efficacy and safety of apixaban versus warfarin in patients with atrial fibrillation and a history of cancer: insights from the ARISTOTLE Trial. Am J Med. 2017;130:1440 1448.e1. 649. Shah S, Norby FL, Datta YH, Lutsey PL, MacLehose RF, Chen LY, Alonso A. Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation. Blood Adv. 2018;2:200 209. 650. Yang P, Zhu D, Xu X, Shen W, Wang C, Jiang Y, Xu G, Wu Q. Efficacy and safety of oral anticoagulants in atrial fibrillation patients with can- cer: a network meta-analysis. Heart Fail Rev. 2020;25:823 831. doi: 651. Dardiotis E, Aloizou AM, Markoula S, Siokas V, Tsarouhas K, Tzanakakis G, Libra M, Kyritsis AP, Brotis AG, Aschner M, et al. Cancer-associated stroke: pathophysiology, detection and management (review). Int J Oncol. 652. Adams HP Jr. Cancer and cerebrovascular disease. Curr Neurol Neurosci Options Neurol. 2002;4:417 425. doi: 10.1007/s11940-002-0009-1 654. Navi BB, Marshall RS, Bobrow D, Singer S, Stone JB, DeSancho MT, DeAngelis LM. Enoxaparin vs aspirin in patients with cancer and isch- emic stroke: the TEACH pilot randomized clinical trial. JAMA Neurol. 655. Adams RJ, McKie VC, Hsu L, Files B, Vichinsky E, Pegelow C, Abboud M, Gallagher D, Kutlar A, Nichols FT, et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med. 1998;339:5 11. doi: 656. Russell MO, Goldberg HI, Hodson A, Kim HC, Halus J, Reivich M, Schwartz E. Effect of transfusion therapy on arteriographic abnormalities and on re- currence of stroke in sickle cell disease. Blood. 1984;63:162 169. 657.


Russell MO, Goldberg HI, Hodson A, Kim HC, Halus J, Reivich M, Schwartz E. Effect of transfusion therapy on arteriographic abnormalities and on re- currence of stroke in sickle cell disease. Blood. 1984;63:162 169. 657. Pegelow CH, Adams RJ, McKie V, Abboud M, Berman B, Miller ST, Olivieri N, Vichinsky E, Wang W, Brambilla D. Risk of recurrent stroke in patients with sickle cell disease treated with erythrocyte transfusions. J Pediatr. 658. Estcourt LJ, Fortin PM, Hopewell S, Trivella M, Wang WC. Blood trans- fusion for preventing primary and secondary stroke in people with sick- le cell disease. Cochrane Database Syst Rev. 2017;1:CD003146. doi: 659. Ware RE, Helms RW; SWiTCH Investigators. Stroke With Transfusions Changing to Hydroxyurea (SWiTCH). Blood. 2012;119:3925 3932. doi: 660. Ali SB, Moosang M, King L, Knight-Madden J, Reid M. Stroke recurrence in children with sickle cell disease treated with hydroxyurea following first clinical stroke. Am J Hematol. 2011;86:846 850. doi: 10.1002/ajh.22142 661. Ware RE, Davis BR, Schultz WH, Brown RC, Aygun B, Sarnaik S, Odame I, Fuh B, George A, Owen W, et al. Hydroxycarbamide versus chronic trans- fusion for maintenance of transcranial Doppler flow velocities in children with sickle cell anaemia: TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial. Lancet. 662. Lucarelli G, Gaziev J, Isgr A, Sodani P, Paciaroni K, Alfieri C, De Angelis G, Marziali M, Simone MD, Gallucci C, et al. Allogeneic cellular gene therapy in hemoglobinopathies: evaluation of hematopoietic SCT in sickle cell anemia. Bone Marrow Transplant. 2012;47:227 230. doi: 10.1038/bmt.2011.79 663. Walters MC, Patience M, Leisenring W, Rogers ZR, Aquino VM, Buchanan GR, Roberts IA, Yeager AM, Hsu L, Adamkiewicz T, et al; Multicenter Investigation of Bone Marrow Transplantation for Sickle Cell Disease.


Walters MC, Patience M, Leisenring W, Rogers ZR, Aquino VM, Buchanan GR, Roberts IA, Yeager AM, Hsu L, Adamkiewicz T, et al; Multicenter Investigation of Bone Marrow Transplantation for Sickle Cell Disease. Stable mixed hematopoietic chimerism after bone marrow transplantation for sickle cell anemia. Biol Blood Marrow Transplant. 2001;7:665 673. doi: 664. Fryer RH, Anderson RC, Chiriboga CA, Feldstein NA. Sickle cell anemia with moyamoya disease: outcomes after EDAS procedure. Pediatr Neurol. 665. Hankinson TC, Bohman LE, Heyer G, Licursi M, Ghatan S, Feldstein NA, Anderson RC. Surgical treatment of moyamoya syndrome in pa- tients with sickle cell anemia: outcome following encephaloduroarte- riosynangiosis. J Neurosurg Pediatr. 2008;1:211 216. doi: 10.3171/ 666. Pleasants S. Epidemiology: a moving target. Nature. 2014;515:S2 S3. doi: 667. Ware RE, de Montalembert M, Tshilolo L, Abboud MR. Sickle cell disease. 668. Piel FB, Patil AP, Howes RE, Nyangiri OA, Gething PW, Dewi M, Temperley WH, Williams TN, Weatherall DJ, Hay SI. Global epidemiology of sickle haemoglobin in neonates: a contemporary geostatistical model-based map and population estimates. Lancet. 2013;381:142 151. doi: 669. Adams RJ, Nichols FT, McKie V, McKie K, Milner P, Gammal TE. Cerebral in- farction in sickle cell anemia: mechanism based on CT and MRI. Neurology. 670. Mack AK, Thompson AA. Primary and secondary stroke prevention in chil- dren with sickle cell disease. J Pediatr Health Care. 2017;31:145 154. 671. DeBaun MR, Gordon M, McKinstry RC, Noetzel MJ, White DA, Sarnaik SA, Meier ER, Howard TH, Majumdar S, Inusa BP, et al. Controlled trial of transfusions for silent cerebral infarcts in sickle cell anemia. N Engl J Med. 672. Brekke LK, Diamantopoulos AP, Fevang BT, A mus J, Esper E, Gjesdal CG. Incidence of giant cell arteritis in western Norway 1972- 2012: a retrospective cohort study. Arthritis Res Ther. 2017;19:278. doi: 673.


Incidence of giant cell arteritis in western Norway 1972- 2012: a retrospective cohort study. Arthritis Res Ther. 2017;19:278. doi: 673. Salvarani C, Macchioni PL, Tartoni PL, Rossi F, Baricchi R, Castri C, Chiaravalloti F, Portioli I. Polymyalgia rheumatica and giant cell arteritis: a 5-year epidemiologic and clinical study in Reggio Emilia, Italy. Clin Exp Rheumatol. 1987;5:205 215. 674. Samson M, Jacquin A, Audia S, Daubail B, Devilliers H, Petrella T, Martin L, Durier J, Besancenot JF, Lorcerie B, et al. Stroke associated with giant CLINICAL STATEMENTS AND GUIDELINES Kleindorfer cell arteritis: a population-based study. J Neurol Neurosurg Psychiatry. 675. Chevalet P, Barrier JH, Pottier P, Magadur-Joly G, Pottier MA, Hamidou M, Planchon B, El Kouri D, Connan L, Dupond JL, et al. A randomized, multicenter, controlled trial using intravenous pulses of methylprednisolone in the initial treatment of simple forms of giant cell arteritis: a one year fol- lowup study of 164 patients. J Rheumatol. 2000;27:1484 1491. 676. Diamantopoulos AP, Haugeberg G, Lindland A, Myklebust G. The fast- track ultrasound clinic for early diagnosis of giant cell arteritis significantly reduces permanent visual impairment: towards a more effective strategy to improve clinical outcome in giant cell arteritis? Rheumatology (Oxford). 677. Gonz lez-Gay MA, Blanco R, Rodr guez-Valverde V, Mart nez-Taboada VM, Delgado-Rodriguez M, Figueroa M, Uriarte E. Permanent visual loss and cerebrovascular accidents in giant cell arteritis: predictors and response to treatment. Arthritis Rheum. 1998;41:1497 1504. doi: 678. Mazlumzadeh M, Hunder GG, Easley KA, Calamia KT, Matteson EL, Griffing WL, Younge BR, Weyand CM, Goronzy JJ. Treatment of giant cell arteri- tis using induction therapy with high-dose glucocorticoids: a double-blind, placebo-controlled, randomized prospective clinical trial. Arthritis Rheum. 679. Lopez-Diaz MJ, Llorca J, Gonzalez-Juanatey C, Pe a-Sagredo JL, Martin J, Gonzalez-Gay MA.


Lopez-Diaz MJ, Llorca J, Gonzalez-Juanatey C, Pe a-Sagredo JL, Martin J, Gonzalez-Gay MA. The erythrocyte sedimentation rate is as- sociated with the development of visual complications in biopsy-proven giant cell arteritis. Semin Arthritis Rheum. 2008;38:116 123. doi: 680. Fern ndez-Fern ndez E, Monjo-Henry I, Bonilla G, Plasencia C, Miranda-Car s ME, Balsa A, De Miguel E. False positives in the ultra- sound diagnosis of giant cell arteritis: some diseases can also show the halo sign. Rheumatology (Oxford). 2020;59:2443 2447. doi: 10.1093/ 681. van der Geest KSM, Borg F, Kayani A, Paap D, Gondo P, Schmidt W, Luqmani RA, Dasgupta B. Novel ultrasonographic Halo Score for gi- ant cell arteritis: assessment of diagnostic accuracy and associa- tion with ocular ischaemia. Ann Rheum Dis. 2020;79:393 399. doi: 682. Mahr AD, Jover JA, Spiera RF, Hern ndez-Garc a C, Fern ndez-Guti rrez B, Lavalley MP, Merkel PA. Adjunctive methotrexate for treatment of gi- ant cell arteritis: an individual patient data meta-analysis. Arthritis Rheum. 683. Stone JH, Tuckwell K, Dimonaco S, Klearman M, Aringer M, Blockmans D, Brouwer E, Cid MC, Dasgupta B, Rech J, et al. Trial of tocilizumab in giant-cell 684. Villiger PM, Adler S, Kuchen S, Wermelinger F, Dan D, Fiege V, B tikofer L, Seitz M, Reichenbach S. Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet. 2016;387:1921 1927. doi: 10.1016/ 685. Onen F, Akkoc N. Epidemiology of Takayasu arteritis. Presse Med. 686. Bond KM, Nasr D, Lehman V, Lanzino G, Cloft HJ, Brinjikji W. Intracranial and extracranial neurovascular manifestations of Takayasu arteritis. AJNR Am J Neuroradiol. 2017;38:766 772. doi: 10.3174/ajnr.A5095 of glucocorticoid-resistant or relapsing Takayasu arteritis with methotrex- ate. Arthritis Rheum. 1994;37:578 582. doi: 10.1002/art.1780370420 688.


2017;38:766 772. doi: 10.3174/ajnr.A5095 of glucocorticoid-resistant or relapsing Takayasu arteritis with methotrex- ate. Arthritis Rheum. 1994;37:578 582. doi: 10.1002/art.1780370420 688. Valsakumar AK, Valappil UC, Jorapur V, Garg N, Nityanand S, Sinha N. Role of immunosuppressive therapy on clinical, immunological, and angiographic outcome in active Takayasu s arteritis. J Rheumatol. 2003;30:1793 1798. 689. de Souza AW, de Almeida Agustinelli R, de Cinque Almeida H, Oliveira PB, Pinheiro FA, Oliveira AC, Sato EI. Leflunomide in Takayasu arteritis: a long term observational study. Rev Bras Reumatol Engl Ed. 2016;56:371 375. 690. Salvarani C, Cantini F, Boiardi L, Hunder GG. Polymyalgia rheumat- ica and giant-cell arteritis. N Engl J Med. 2002;347:261 271. doi: 691. Salvarani C, Brown RD Jr, Calamia KT, Christianson TJ, Weigand SD, Miller DV, Giannini C, Meschia JF, Huston J 3rd, Hunder GG. Primary central nervous system vasculitis: analysis of 101 patients. Ann Neurol. 692. Boulouis G, de Boysson H, Zuber M, Guillevin L, Meary E, Costalat V, Pagnoux C, Naggara O; French Vasculitis Group. Primary angiitis of the central nervous system: magnetic resonance imaging spectrum of parenchymal, meningeal, and vascular lesions at baseline. Stroke. 693. Hutchinson C, Elbers J, Halliday W, Branson H, Laughlin S, Armstrong D, Hawkins C, Westmacott R, Benseler SM. Treatment of small vessel pri- mary CNS vasculitis in children: an open-label cohort study. Lancet Neurol. 694. Salvarani C, Brown RD Jr, Christianson TJ, Huston J 3rd, Giannini C, Miller DV, Hunder GG. Adult primary central nervous system vasculitis treat- ment and course: analysis of one hundred sixty-three patients. Arthritis 695. de Boysson H, Arquizan C, Touz E, Zuber M, Boulouis G, Naggara O, Guillevin L, Aouba A, Pagnoux C. Treatment and long-term outcomes of primary central nervous system vasculitis. Stroke. 2018;49:1946 1952. 696.


Arthritis 695. de Boysson H, Arquizan C, Touz E, Zuber M, Boulouis G, Naggara O, Guillevin L, Aouba A, Pagnoux C. Treatment and long-term outcomes of primary central nervous system vasculitis. Stroke. 2018;49:1946 1952. 696. Schuster S, Ozga AK, Stellmann JP, Deb-Chatterji M, H u ler V, Matschke J, Gerloff C, Thomalla G, Magnus T. Relapse rates and long-term outcome in primary angiitis of the central nervous system. J Neurol. 2019;266:1481 697. Hoffman GS, Cid MC, Rendt-Zagar KE, Merkel PA, Weyand CM, Stone JH, Salvarani C, Xu W, Visvanathan S, Rahman MU; Infliximab-GCA Study Group. Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. Ann Intern Med. 2007;146:621 698. Liou TH, Huang SW, Lin JW, Chang YS, Wu CW, Lin HW. Risk of stroke in patients with rheumatism: a nationwide longitudinal population-based study. Sci Rep. 2014;4:5110. doi: 10.1038/srep05110 699. Stojan G, Petri M. Atherosclerosis in systemic lupus erythemato- sus. J Cardiovasc Pharmacol. 2013;62:255 262. doi: 10.1097/ 700. Moyssakis I, Tektonidou MG, Vasilliou VA, Samarkos M, Votteas V, Moutsopoulos HM. Libman-Sacks endocarditis in systemic lupus erythematosus: prevalence, associations, and evolution. Am J Med. 701. Fasano S, Pierro L, Pantano I, Iudici M, Valentini G. Longterm hydroxy- chloroquine therapy and low-dose aspirin may have an additive effective- ness in the primary prevention of cardiovascular events in patients with systemic lupus erythematosus. J Rheumatol. 2017;44:1032 1038. doi: 702. Law ST, Ma KM, Li KK. Clinical characteristics of concurrent and se- quentially presented lupus-related protein-losing enteropathy: what are their differences? Rheumatol Int. 2013;33:85 92. doi: 10.1007/ 703. Shapiro M, Levy Y. The association between hydroxychloroquine treat- ment and cardiovascular morbidity among rheumatoid arthritis patients. 704.


The association between hydroxychloroquine treat- ment and cardiovascular morbidity among rheumatoid arthritis patients. 704. Sharma TS, Wasko MCM, Tang X, Vedamurthy D, Yan X, Cote J, Bili A. Hydroxychloroquine use is associated with decreased incident car- diovascular events in rheumatoid arthritis patients. J Am Heart Assoc. 705. Varona JF, Guerra JM, Bermejo F, Molina JA, Gomez de la C mara A. Causes of ischemic stroke in young adults, and evolution of the etio- logical diagnosis over the long term. Eur Neurol. 2007;57:212 218. doi: 706. Emmi G, Silvestri E, Squatrito D, Amedei A, Niccolai E, D Elios MM, Della Bella C, Grassi A, Becatti M, Fiorillo C, et al. Thrombosis in vas- culitis: from pathogenesis to treatment. Thromb J. 2015;13:15. doi: 707. Weyand CM, Goronzy JJ. Immune mechanisms in medium and large-vessel vasculitis. Nat Rev Rheumatol. 2013;9:731 740. doi: 708. Stamatis P. Giant cell arteritis versus Takayasu arteritis: an update. Mediterr J Rheumatol. 2020;31:174 182. doi: 10.31138/mjr.31.2.174 709. Hellmich B, Agueda A, Monti S, Buttgereit F, de Boysson H, Brouwer E, Cassie R, Cid MC, Dasgupta B, Dejaco C, et al. 2018 Update of the EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis. 2020;79:19 30. doi: 10.1136/annrheumdis-2019-215672 710. Gutierrez J, Ortiz G. HIV/AIDS patients with HIV vasculopathy and VZV vasculitis: a case series. Clin Neuroradiol. 2011;21:145 151. doi: 711. Lanthier S, Armstrong D, Domi T, deVeber G. Post-varicella arteriopathy of childhood: natural history of vascular stenosis. Neurology. 2005;64:660 712. Nagel MA, Forghani B, Mahalingam R, Wellish MC, Cohrs RJ, Russman AN, Katzan I, Lin R, Gardner CJ, Gilden DH. The value of detecting CLINICAL STATEMENTS AND GUIDELINES Kleindorfer anti-VZV IgG antibody in CSF to diagnose VZV vasculopathy. Neurology. 713.


The value of detecting CLINICAL STATEMENTS AND GUIDELINES Kleindorfer anti-VZV IgG antibody in CSF to diagnose VZV vasculopathy. Neurology. 713. Nagel MA, Cohrs RJ, Mahalingam R, Wellish MC, Forghani B, Schiller A, Safdieh JE, Kamenkovich E, Ostrow LW, Levy M, et al. The varicella zoster vi- rus vasculopathies: clinical, CSF, imaging, and virologic features. Neurology. 714. Wallace MR, Bowler WA, Murray NB, Brodine SK, Oldfield EC 3rd. Treatment of adult varicella with oral acyclovir: a randomized, pla- cebo-controlled trial. Ann Intern Med. 1992;117:358 363. doi: 715. Blocker ME, Levine WC, St Louis ME. HIV prevalence in patients with syphilis, United States. Sex Transm Dis. 2000;27:53 59. doi: 716. Callegari FM, Pinto-Neto LF, Medeiros CJ, Scopel CB, Page K, Miranda AE. Syphilis and HIV co-infection in patients who attend an AIDS outpatient clinic in Vitoria, Brazil. AIDS Behav. 2014;18(suppl 1):S104 S109. doi: 717. G nthard HF, Aberg JA, Eron JJ, Hoy JF, Telenti A, Benson CA, Burger DM, Cahn P, Gallant JE, Glesby MJ, et al; International Antiviral Society- USA Panel. Antiretroviral treatment of adult HIV infection: 2014 recom- mendations of the International Antiviral Society-USA Panel. JAMA. 718. Connor M. Human immunodeficiency virus (HIV) and stroke: tar- gets for intervention. Infect Disord Drug Targets. 2010;10:76 83. doi: 719. Connor MD. Treatment of HIV associated cerebral vasculopathy. J Neurol Neurosurg Psychiatry. 2009;80:831. doi: 10.1136/jnnp.2008.169490 720. Cutfield NJ, Steele H, Wilhelm T, Weatherall MW. Successful treatment of HIV associated cerebral vasculopathy with HAART. J Neurol Neurosurg 721. Mart nez-Longoria CA, Morales-Aguirre JJ, Villalobos-Acosta CP, G mez-Barreto D, Cashat-Cruz M. Occurrence of intracerebral aneurysm in an HIV-infected child: a case report. Pediatr Neurol. 2004;31:130 132. 722. Benjamin LA, Allain TJ, Mzinganjira H, Connor MD, Smith C, Lucas S, Joekes E, Kampondeni S, Chetcuti K, Turnbull I, et al.


Benjamin LA, Allain TJ, Mzinganjira H, Connor MD, Smith C, Lucas S, Joekes E, Kampondeni S, Chetcuti K, Turnbull I, et al. The role of human immunodeficiency virus-associated vasculopathy in the etiology of stroke. J Infect Dis. 2017;216:545 553. doi: 10.1093/infdis/jix340 723. Goldstein DA, Timpone J, Cupps TR. HIV-associated intracranial an- eurysmal vasculopathy in adults. J Rheumatol. 2010;37:226 233. doi: 724. Saraya T, Shimura C, Wada H, Aoshima M, Goto H. Evidence for vascular spread of varicella zoster-associated vasculopathy. Ann Intern Med. 2006; 725. WHO Secretariat. Chagas disease: control and elimination. 63th World Health Assembly. 2010. Provisional agenda item 11.14. Accessed 726. Carod-Artal FJ, Gascon J. Chagas disease and stroke. Lancet Neurol. 727. Lima-Costa MF, Matos DL, Ribeiro AL. Chagas disease predicts 10-year stroke mortality in community-dwelling elderly: the Bambui Cohort Study of Aging. Stroke. 2010;41:2477 2482. doi: 10.1161/ 728. de Sousa AS, Xavier SS, Rodriguez de Freitas GR, Hasslocher-Moreno A. Prevention strategies of cardioembolic ischemic stroke in Chagas disease. Arq Bras Cardiol. 2008;91:306 310. doi: 10.1590/s0066- 729. Connor MD, Lammie GA, Bell JE, Warlow CP, Simmonds P, Brettle RD. Cerebral infarction in adult AIDS patients: observations from the Edinburgh HIV Autopsy Cohort. Stroke. 2000;31:2117 2126. doi: 730. Morgello S, Mahboob R, Yakoushina T, Khan S, Hague K. Autopsy find- ings in a human immunodeficiency virus-infected population over 2 decades: influences of gender, ethnicity, risk factors, and time. Arch Pathol Lab Med. 2002;126:182 190. doi: 10.1043/0003- 731. Misra UK, Kalita J, Maurya PK. Stroke in tuberculous meningitis. J Neurol 732. Anderson NE, Somaratne J, Mason DF, Holland D, Thomas MG. Neurological and systemic complications of tuberculous meningitis and its treatment at Auckland City Hospital, New Zealand. J Clin Neurosci. 733.


Neurological and systemic complications of tuberculous meningitis and its treatment at Auckland City Hospital, New Zealand. J Clin Neurosci. 733. Cordato DJ, Djekic S, Taneja SR, Maley M, Beran RG, Cappelen-Smith C, Griffith NC, Hanna IY, Hodgkinson SJ, Worthington JM, et al. Prevalence of positive syphilis serology and meningovascular neurosyphilis in patients admitted with stroke and TIA from a culturally diverse population (2005- 734. Mishra AK, Arvind VH, Muliyil D, Kuriakose CK, George AA, Karuppusami R, Benton Carey RA, Mani S, Hansdak SG. Cerebrovascular in- jury in cryptococcal meningitis. Int J Stroke. 2018;13:57 65. doi: 735. Workowski KA, Bolan GA; Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep. 2015;64:1 137. 736. Fonkem E, Dayawansa S, Stroberg E, Lok E, Bricker PC, Kirmani B, Wong ET, Huang JH. Neurological presentations of intravascular lym- phoma (IVL): meta-analysis of 654 patients. BMC Neurol. 2016;16:9. doi: 737. Patil A, Shree R, Naheed D, Goyal MK, Mehta S, Ahuja CK, Radotra BD, Lal V. Pearls & oy-sters: paraneoplastic cerebral vasculitis: rare cause of spon- taneous convexity subarachnoid hemorrhage. Neurology. 2018;90:e815 738. Quinones E, Potes LI, Silva N, Lobato-Polo J. Lymphomatoid granulomato- sis of the brain: a case report. Surg Neurol Int. 2016;7(suppl 23):S612 739. Yap S, Naughten E. Homocystinuria due to cystathionine beta-synthase de- ficiency in Ireland: 25 years experience of a newborn screened and treat- ed population with reference to clinical outcome and biochemical control. J Inherit Metab Dis. 1998;21:738 747. doi: 10.1023/a:1005445132327 740. Yap S, Naughten ER, Wilcken B, Wilcken DE, Boers GH. Vascular complications of severe hyperhomocysteinemia in patients with ho- mocystinuria due to cystathionine beta-synthase deficiency: effects of ho- mocysteine-lowering therapy. Semin Thromb Hemost. 2000;26:335 340. 741. El Dib R, Gomaa H, Carvalho RP, Camargo SE, Bazan R, Barretti P, Barreto FC.


El Dib R, Gomaa H, Carvalho RP, Camargo SE, Bazan R, Barretti P, Barreto FC. Enzyme replacement therapy for Anderson-Fabry disease. Cochrane Database Syst Rev. 2016;7:CD006663. doi: 742. Germain DP, Elliott PM, Falissard B, Fomin VV, Hilz MJ, Jovanovic A, Kantola I, Linhart A, Mignani R, Namdar M, et al. The effect of enzyme replacement therapy on clinical outcomes in male patients with Fabry dis- ease: a systematic literature review by a European panel of experts. Mol Genet Metab Rep. 2019;19:100454. doi: 10.1016/j.ymgmr.2019.100454 743. Rolfs A, B ttcher T, Zschiesche M, Morris P, Winchester B, Bauer P, Walter U, Mix E, L hr M, Harzer K, et al. Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study. Lancet. 2005;366:1794 744. Wozniak MA, Kittner SJ, Tuhrim S, Cole JW, Stern B, Dobbins M, Grace ME, Nazarenko I, Dobrovolny R, McDade E, et al. Frequency of unrec- ognized Fabry disease among young European-American and African- American men with first ischemic stroke. Stroke. 2010;41:78 81. doi: 745. Bersano A, Kraemer M, Burlina A, Mancuso M, Finsterer J, Sacco S, Salvarani C, Caputi L, Chabriat H, Oberstein SL, et al. Heritable and non-heritable uncommon causes of stroke [published on- line April 21, 2020]. J Neurol. doi: 10.1007/s00415-020-09836-x. 746. Koga Y, Povalko N, Inoue E, Nakamura H, Ishii A, Suzuki Y, Yoneda M, Kanda F, Kubota M, Okada H, et al. Therapeutic regimen of L-arginine for MELAS: 9-year, prospective, multicenter, clinical research. J Neurol. 747. El-Hattab AW, Almannai M, Scaglia F. Arginine and citrulline for the treat- ment of MELAS syndrome. J Inborn Errors Metab Screen. 2017;5:10.1177 748. Haussen DC, Grossberg JA, Bouslama M, Pradilla G, Belagaje S, Bianchi N, Allen JW, Frankel M, Nogueira RG. Carotid web (intimal fibromuscular dysplasia) has high stroke recurrence risk and is amenable to stenting. 749.


Carotid web (intimal fibromuscular dysplasia) has high stroke recurrence risk and is amenable to stenting. 749. Haussen DC, Grossberg JA, Koch S, Malik A, Yavagal D, Gory B, Leesch W, Hassan AE, Derelle AL, Richard S, et al. Multicenter experience with stenting for symptomatic carotid web. Interv Neurol. 2018;7:413 418. doi: 750. Zhang AJ, Dhruv P, Choi P, Bakker C, Koffel J, Anderson D, Kim J, Jagadeesan B, Menon BK, Streib C. A systematic literature review of pa- tients with carotid web and acute ischemic stroke. Stroke. 2018;49:2872 751. Coutinho JM, Derkatch S, Potvin AR, Tomlinson G, Casaubon LK, Silver FL, Mandell DM. Carotid artery web and ischemic stroke: a case-control study. CLINICAL STATEMENTS AND GUIDELINES Kleindorfer 752. Gornik HL, Persu A, Adlam D, Aparicio LS, Azizi M, Boulanger M, Bruno RM, de Leeuw P, Fendrikova-Mahlay N, Froehlich J, et al. First international consensus on the diagnosis and management of fibromuscular dysplasia. Vasc Med. 2019;24:164 189. doi: 10.1177/1358863X18821816 753. Weinberg I, Gu X, Giri J, Kim SE, Bacharach MJ, Gray BH, Katzen BT, Matsumoto AH, Chi YW, Rogers KR, et al. Anti-platelet and anti-hyper- tension medication use in patients with fibromuscular dysplasia: results from the United States Registry for Fibromuscular Dysplasia. Vasc Med. 754. Smith LL, Smith DC, Killeen JD, Hasso AN. Operative balloon angioplasty in the treatment of internal carotid artery fibromuscular dysplasia. J Vasc 755.


Operative balloon angioplasty in the treatment of internal carotid artery fibromuscular dysplasia. J Vasc 755. Olin JW, Gornik HL, Bacharach JM, Biller J, Fine LJ, Gray BH, Gray WA, Gupta R, Hamburg NM, Katzen BT, et al; on behalf of the American Heart Association Council on Peripheral Vascular Disease; American Heart Association Council on Clinical Cardiology; American Heart Association Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation; American Heart Association Council on Cardiovascular Disease in the Young; American Heart Association Council on Cardiovascular Radiology and Intervention; American Heart Association Council on Epidemiology and Prevention; American Heart Association Council on Functional Genomics and Translational Biology; American Heart Association Council for High Blood Pressure Research; American Heart Association Council on the Kidney in Cardiovascular Disease; American Heart Association Stroke Council. Fibromuscular dysplasia: state of the science and critical unanswered questions: a scientific statement from the American Heart Association. Circulation. 2014;129:1048 1078. doi: 756. Olin JW, Froehlich J, Gu X, Bacharach JM, Eagle K, Gray BH, Jaff MR, Kim ES, Mace P, Matsumoto AH, et al. The United States Registry for Fibromuscular Dysplasia: results in the first 757. De Groote M, Van der Niepen P, Hemelsoet D, Callewaert B, Vermassen F, Billiouw JM, De Vriese A, Donck J, De Backer T. Fibromuscular dysplasia: results of a multicentre study in Flanders. Vasa. 2017;46:211 218. doi: 758. Schievink WI. Spontaneous dissection of the carotid and verte- bral arteries. N Engl J Med. 2001;344:898 906. doi: 10.1056/ 759. Kadian-Dodov D, Gornik HL, Gu X, Froehlich J, Bacharach JM, Chi YW, Gray BH, Jaff MR, Kim ES, Mace P, et al. Dissection and aneurysm in pa- tients with fibromuscular dysplasia: findings from the U.S. Registry for FMD. J Am Coll Cardiol. 2016;68:176 185. doi: 10.1016/j.jacc.2016.04.044 760. Passero SG, Rossi S. Natural history of vertebrobasilar dolichoectasia. 761.